



BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Methodology of the BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>BMJ Open</i>  |
| Manuscript ID                 | bmjopen-2022-066057  |
| Article Type:                 | Protocol   |
| Date Submitted by the Author: | 27-Jun-2022  |
| Complete List of Authors:     | <p>Reilev, Mette; University of Southern Denmark, Clinical Pharmacology, Pharmacy and Environmental Medicine</p> <p>Jensen, Peter Bjødstrup; University of Southern Denmark, Clinical Pharmacology, Pharmacy and Environmental Medicine</p> <p>Ranch, Lise Skov; LEO Pharma A/S, Biostatistics and Pharmacoepidemiology</p> <p>Egeberg, A; Gentofte Hospital, Department of Dermatology and Allergy</p> <p>Furu, Kari; Norwegian Institute of Public Health, Department of Pharmacoepidemiology</p> <p>Gembert, Karin; Karolinska Institute</p> <p>Hagg, David; Karolinska Institute</p> <p>Haug, Ulrike; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Clinical Epidemiology; High-Profile Research Area Health Sciences, University of Bremen</p> <p>Karlstad, Øystein; Nasjonalt folkehelseinstitutt, Department of Chronic Diseases</p> <p>Reutfors, Johan; Karolinska Institute</p> <p>Schäfer, Wiebke; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Clinical Epidemiology</p> <p>Schwartz, Sarina; 6. Leibniz-Institute for Prevention Research and Epidemiology-BIPS</p> <p>Smits, Elisabeth; PHARMO Institute for Drug Outcomes Research</p> <p>Holthius, Emily; PHARMO Institute for Drug Outcomes Research</p> <p>Herings, Ron; PHARMO Institute for Drug Outcomes Research; Vrije Universiteit Amsterdam</p> <p>Trifirò, Gianluca; University of Verona, Department of Diagnostics and Public Health</p> <p>Kirchmayer, Ursula; Department of Epidemiology, Regional Health Service, Lazio Region.</p> <p>Rosa, Alessandro Cesare; Lazio Regional Health Service, Department of Epidemiology</p> <p>Belleudi, Valeria; Department of Epidemiology, Lazio Regional Health Service; ASL Roma 1</p> <p>Gini, Rosa; Agenzia regionale di sanità della Toscana, Epidemiology Unit; Erasmus Medical Center, Medical Informatics</p> <p>Støvring, Henrik; University of Southern Denmark, Clinical Pharmacology, Pharmacy and Environmental Medicine</p> <p>Hallas, Jesper; University of Southern Denmark, Clinical Pharmacology</p> |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

|           |   |
|-----------|---|
| Keywords: | Psoriasis < DERMATOLOGY, Adverse events < THERAPEUTICS, INFECTIOUS DISEASES, CARDIOLOGY, Suicide & self-harm < PSYCHIATRY, ONCOLOGY |
|           |   |

SCHOLARONE™  
Manuscripts

Methodology of the BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS)  
study in electronic healthcare databases

Target journal: BMJ Open, Protocol manuscript

Authors: Mette Reilev<sup>1</sup>, Peter Bjødstrup Jensen<sup>1</sup>, Lise Skov Ranch<sup>2</sup>, Alexander Egeberg<sup>3</sup>, Kari Furu<sup>4</sup>, Karin Gembert<sup>5</sup>, David Hägg<sup>5</sup>, Ulrike Haug<sup>6, 7</sup>, Øystein Karlstad<sup>4</sup>, Johan Reutfors<sup>5</sup>, Wiebke Schaefer<sup>6</sup>, Sarina Schwartz<sup>6</sup>, Elisabeth Smits<sup>8</sup>, Emily Holthius<sup>8</sup>, Ron Herings<sup>8, 9</sup>, Gianluca Trifirò<sup>10</sup>, Ursula Kirchmayer<sup>11</sup>, Alessandro Cesare Rosa<sup>11</sup>, Valeria Belleudi<sup>11</sup>, Rosa Gini<sup>12</sup>, Henrik Støvring<sup>1</sup>, Jesper Hallas<sup>1</sup> on behalf of the BRAHMS study group

Affiliations:

1. Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark
2. Biostatistics and Pharmacoepidemiology, Medical Sciences, LEO Pharma A/S, Denmark
3. Copenhagen University Hospital Bispebjerg, Denmark.
4. Department of Chronic Diseases, Norwegian Institute of Public Health, Norway
5. Karolinska Institute, Sweden
6. Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Germany
7. Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany
8. PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands
9. Amsterdam UMC, Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, Netherlands
10. Department of Diagnostics and Public Health, University of Verona, Italy
11. Department of Epidemiology, ASL Roma 1, Lazio Regional Health Service, Italy
12. Agenzia Regionale di Sanità, Tuscany, Italy

Word count: Abstract: 335; Text: 3549 excluding Boxes 1 and 2

Correspondence:

Mette Reilev  
Clinical Pharmacology, Pharmacy and Environmental Medicine  
University of Southern Denmark  
JB Winslows Vej 19,2, 5000 Odense C  
mreilev@health.sdu.dk

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

*Introduction*

Safe and effective pharmacological treatment is of paramount importance for treating severe psoriasis. Brodalumab, a monoclonal antibody against interleukin (IL) 17 receptor A, was granted marketing authorization in the EU in 2017. The European Medicines Agency requested a post-authorization safety study of brodalumab to address potential safety issues raised during drug development regarding major adverse cardiovascular events (MACE), suicidal conduct, cancer and serious infections.

*Methods and analysis*

BRAHMS is a multicentre observational safety study of brodalumab running from 2017 to 2029 and using a network of population-based healthcare databases from Denmark, Sweden, Norway, Netherlands, Germany and 3 different centres in Italy. The study is conducted using a distributed database network approach, such that only aggregate data are exchanged between sites.

Two types of designs are used: a case-time-control design to study acute effects of transient treatment and a variation of the new user active comparator design to study the effects of transient or chronic treatment. As comparators, inhibitors of TNF- $\alpha$ , inhibitors of IL-12 and IL-23, and other inhibitors of cytokine IL-17A are included.

In the self-controlled case-time-control design, the risk of developing the outcome of interest during periods of brodalumab use is compared within individuals to the risk in periods without use.

In the active comparator cohort design, new users of brodalumab are identified and matched to new users of active comparators. Potential baseline confounders are adjusted for by using propensity score modelling. For outcomes that potentially require large cumulative exposure (cancer and MACE), a specifically adapted active comparator design has been developed.

*Ethics and dissemination*

This being an observational study, the main ethical issue is protection of data confidentiality, which is secured by the distributed network approach. Results will be published in peer-reviewed journals.

### *Study registration*

The BRAHMS study is registered in the EU - PASS register (EUPAS30280).

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Strengths and limitations of this study**

This 12-year long, multinational, observational study addresses potential safety issues raised during drug development i.e., the identified risk of serious infections and the potential risk of suicidal conduct, major adverse cardiac events, and cancer.

Acknowledging the diverse biological mechanisms behind potential risks related to use of brodalumab, the self-controlled, case-time-control design and variations of the active comparator cohort design are used.

To reduce limitations related to heterogeneity of data sources and coding practices across participating countries, a comprehensive infrastructure has been built including a BRAHMS common data model and a component-composite framework for study variable definitions.

As an important collateral benefit of the study, we build network, experience, methodology and infrastructure, which allows for a timely and scientifically rigorous investigation of future safety issues, especially in the area of biologic drug use in psoriasis and other immune mediated inflammatory diseases.

## Introduction

Psoriasis is a chronic immune mediated inflammatory skin disease affecting 2 to 3% of adults in western countries[1,2]. Safe and efficacious pharmacological treatments of moderate to severe psoriasis is important to improve quality of life and prevent serious comorbidities in these patients.

An increasing number of biological therapies for the treatment of moderate to severe psoriasis have become available over the last two decades. The patients can profit from this as treatment switches between approved drugs are often needed due to lack of response, tolerability issues, or treatment fatigue[3]. Brodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adults and was granted Marketing Authorization in the EU in 2017. It is a fully human immunomodulatory monoclonal antibody that binds to human interleukin 17 receptor A (IL17 A).

The safety of brodalumab has been investigated in clinical trials including the two pivotal phase III clinical trials AMAGINE-2 and AMAGINE-3[4–6]. In the regulatory processing of the marketing authorisation, specific aspects of long-term safety were agreed to be further investigated as part of the risk management plan for brodalumab. This included the risk of serious infections, suicidal ideation and behaviour, major adverse cardiac event (MACE) and malignancies. The concern for serious infections, MACE and cancer are shared by other biologics approved for the treatment of immune mediated inflammatory diseases and originate from the products' immunomodulatory activity[7]. As brodalumab binds to IL-17 A, the role of IL-17 and the correspondent IL-17 RA in the host defence against bacterial and fungal infections prompts for investigation of the risk of infections in brodalumab treated patients[8]. Some instances of suicidal conduct were observed during the development program[4], but due to the rarity of these events, trial data were inconclusive as to whether brodalumab treated individuals had an excess risk. Psychiatric comorbidity, including suicidality, is well known in psoriasis patients[9,10], and a potential association between suicidal conduct and brodalumab is not substantiated by any known underlying biological mechanism[11]. Psoriasis patients have an increased risk of cardiovascular events[12]. However, the impact of treatment with systemic biologics on the general cardiovascular comorbidity in psoriasis patients is debated[13] and no specific evidence exists for brodalumab. While the results from most studies of the risk of malignancies in psoriasis patients treated with systemic biologics are reassuring, evidence from long-term studies is limited[14]. These risks are therefore to be investigated in a post-



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

authorization safety study i.e., the BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study.

**Methods and analysis**

The BRAHMS study is a European multinational observational study using electronic healthcare data covering the period from the first authorization date of brodalumab in Europe (July 2017) until the extraction of the final dataset in 2029. The study intends to evaluate a potential excess risk of serious infections, suicidal conduct (including death by suicide and suicide attempt), MACE, and cancer associated with brodalumab treatment in patients with psoriasis by applying the case-time-control design and variations of the active comparator cohort design adapted to new use, current use, ever-use and high cumulative use.

**Data sources**

The BRAHMS study is conducted in a collaboration between research groups from Denmark (University of Southern Denmark), Sweden (Karolinska Institute), Norway (Norwegian Institute of Public Health), Germany (Leibniz Institute for Prevention Research and Epidemiology - BIPS), the Netherlands (PHARMO Database Network), and Italy (Tuscany (Agenzia Regionale di Sanità), Caserta local health unit (University of Verona), and Lazio (Lazio Regional Health Service)). **Table 1** provides an overview of local population-based electronic healthcare databases included in the study.

**Table 1.** Overview of data sources from each participating site.

|   | <b>Denmark</b>                   | <b>Sweden</b>                        | <b>Norway</b>  | <b>Netherlands</b> | <b>Germany</b>      | <b>Tuscany</b>                   | <b>Caserta</b>               | <b>Lazio</b>                   |
|---|----------------------------------|--------------------------------------|--|--------------------|---------------------|----------------------------------|------------------------------|--------------------------------|
| Individuals covered (% of country pop)                                | 5.7 mill<br>(100%)               | 10 mill<br>(100%)                    | 5.2 mill<br>(100%)   | 4 mill<br>(25%)    | 20 mill<br>(25%)    | 3.6 mill<br>(6%)                 | 1.1 mill<br>(1.8%)           | 5.7 mill<br>(9.5%)             |
| Data source name / data owner   | The Danish Health Data Authority | National Board of Health and Welfare | Norwegian Health and socioeconomic data authorities <sup>4</sup> | PHARMO             | GePaRD <sup>5</sup> | Tuscany regional claims database | Caserta LHU claims databases | Lazio regional claims database |
| <b>Included data types / settings</b>                                 |                                  |                                      |  |                    |                     |                                  |                              |                                |
| Inpatient hospital care   | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Outpatient hospital care  | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes <sup>6</sup>    | No                               | No                           | No                             |
| Emergency room care   | Yes                              | Yes                                  | Yes  | No                 | Yes <sup>7</sup>    | Yes                              | Yes                          | Yes                            |
| Non-hospital specialist care  | No                               | No                                   | Yes  | No                 | Yes                 | No                               | No                           | No                             |
| General practice care   | No                               | No                                   | Yes  | Yes <sup>1</sup>   | No                  | No                               | No                           | No                             |
| Inpatient drug dispensings  | Yes <sup>2</sup>                 | No                                   | Yes  | Yes <sup>1</sup>   | Yes <sup>2</sup>    | No                               | No                           | No                             |
| Outpatient pharmacy dispensed prescription drugs                      | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Civil registration data   | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Cancer register   | Yes                              | Yes                                  | Yes  | No                 | No                  | No                               | No                           | No                             |
| Causes of death register  | Yes                              | Yes                                  | Yes  | No                 | No                  | Yes                              | Yes                          | Yes                            |
| Socio-economy   | No                               | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Pathology register  | No                               | No                                   | No   | No                 | No                  | No                               | No                           | No                             |
| Exemption from copayment register (Italy)                             | No                               | No                                   | No   | No                 | No                  | Yes                              | Yes                          | Yes                            |
| Data availability prior to start of study period <sup>3</sup> (Years) | 15+                              | 12+                                  | 10+  | 15+                | 10-15               | 10+                              | 10+                          | 10+                            |
| <b>Coding systems used</b>  |                                  |                                      |  |                    |                     |                                  |                              |                                |

|            |                       |                       |                 |                        |        |         |         |         |
|------------|-----------------------|-----------------------|-----------------|------------------------|--------|---------|---------|---------|
| Diagnoses  | ICD10                 | ICD10                 | ICD10, ICPC-2   | ICD10, ICD9-CM, ICPC-2 | ICD10  | ICD9-CM | ICD9-CM | ICD9-CM |
| Medication | ATC                   | ATC                   | ATC             | ATC                    | ATC    | ATC     | ATC     | ATC     |
| Procedures | Nomesco (SKS), Custom | Nomesco (KVÅ), Custom | Nomesco, Custom | Custom                 | Custom | ICD9-CM | ICD9-CM | ICD9-CM |

<sup>1</sup> Data collection periods, catchment area and overlap between PHARMO data sources differ

<sup>2</sup> Possible to identify some drugs dispensings such as biologics from procedure codes with limited dosing information

<sup>3</sup> Covered by at least drug dispensing and inpatient hospital data

<sup>4</sup> Linked nationwide data from different register holders in Norway

<sup>5</sup> Based on claims data from 4 German statutory health insurance providers

<sup>6</sup> Excluding endoscopic and surgical procedures

<sup>7</sup> Cannot be distinguished from other hospital care

ICD10: International Classification of Disease 10<sup>th</sup> revision; ICD9-CM: Internation Classification of Disease-9<sup>th</sup> Revision – Clinical Modification; ICPC: International Classification of Primary Care; ATC: Anatomical Therapeutic Classification; Nomesco: Nordic classification of surgical procedures

Common to all collaborating sites is the availability of inpatient hospital data or hospital discharge diagnoses as well as pharmacy claims data with at least 10 years of coverage leading up to study start. Other relevant data sources such as outpatient and primary care data are included but may differ between sites in terms of availability or level of coverage. Linkage between data sources is possible within each site through unique and pseudonymized person identifiers. Depending on the site, local clinical data are encoded using either the ICD-9-CM, ICD-10 or ICPC-2 (primary care) classifications. The ATC classification is generally used to code drug dispensing at all sites. Since dispensing, registration and coding practices for biologics differ by country, some sites will also use procedure codes to identify these dispensing from hospital data. In total, the participating sites have access to data covering a population of approximately 50 million people from 6 European Countries.

### ***Study design***

A major challenge of the BRAHMS study is the inherently increased risk of comorbidities, such as psychiatric and cardiovascular diseases, among psoriasis patients relative to the background population, which may induce confounding by indication. For example, rates of suicidal acts are 42% higher in this patient population than in healthy individuals[10]. To mitigate unmeasured confounding by underlying psoriasis severity, two designs are used; a self-controlled, case-time-control design[15] and variations of an active comparator cohort design[16].

The case-time-control design is appropriate in studies of a transient effect of ongoing exposure related to an abrupt outcome, e.g., in the analysis of suicidal conduct, where a potential risk hereof is expected to increase directly after initiation of the drug and fade immediately after discontinuation. The choice of the case-time-control design among the self-controlled designs was motivated by the fact that some of the outcomes carry a high mortality, which invalidates the bidirectional self-controlled designs, such as the self-controlled case series or symmetry design[17]. In addition, exposure to a given biologic is likely to be chronic, which in a classic case-crossover design would induce persistent user bias[18]. The case-time-control design has been shown to adjust for persistent user bias[19].

To address the diverse nature of the outcomes, we use variations of the active comparator cohort design. From a biological reasoning, a serious infection is likely to be a short-term outcome of brodalumab exposure that can be investigated by employing the new user, active

comparator cohort design. Cancer, on the other hand, is more likely to be caused by a cumulative effect. Hence, neither the case-time-control design nor the new user, active comparator cohort design is suitable to investigate the association of brodalumab use and cancer. Instead, we employ an ever-user approach of the active comparator cohort design and we have developed a comparative design, which is specifically adapted to analysis of cumulative exposures (see below). An overview of the designs employed for each of the outcomes is shown in **Table 2**. Specifications of each design is detailed under “Analysis”.

**Table 2.** Overview of design choices for the Brodalumab Assessment of Hazards; a Multinational Safety (BRAHMS) study. See text for specifications.

|   | Serious infections | Suicidal conduct | MACE | Cancer |
|---|--------------------|------------------|------|--------|
| New use, comparative cohort design        | X                  | X                | X    |        |
| Current use, comparative cohort design    | X                  | X                | X    |        |
| Ever-use, comparative cohort design       |                    |                  | X    | X      |
| Cumulative use, comparative cohort design |                    |                  | X    | X      |
| Case-time-control design                  | X                  | X                | X    |        |

**Study cohorts**

For the wide range of analyses in the BRAHMS study, different study cohorts are created in a two step-process; the first step is the creation of a general study cohort while the second step is the creation of analysis specific cohorts.

Individuals enter the general study cohort on the date of the earliest recording within the study period of a biologic used in the treatment of psoriasis. Individuals are censored if another probable indication for receiving biological therapy is registered, if two or more biologics are registered on the same date, in case of loss of data coverage, death, or end of study period. This step creates an eligibility period for every included individual during which any occurring

treatment episode and outcome may contribute to a specific analysis. Inclusion- and exclusion criteria for the general study cohort are described in **Box 1** and visualized in **Figure 1**.

**Box 1.** Inclusion- and exclusion criteria for the general study cohort. Due to data source heterogeneity, site-specific adaptations are allowed.

#### *Inclusion Criteria*

**Probable psoriasis diagnosis.** The general study cohort entry date (CED) must be preceded by, or coincide with, a record of a psoriasis diagnosis code or other method of ascertainment of psoriasis e.g., use of topical vitamin D3 derivatives or a recording of a disease specific copayment exemption code.

**Qualification of indication for receiving biological therapy (optional).** If relevant, each site may impose additional criteria that ascertain that psoriasis is the most likely indication for the biological treatment dispensed at the CED. This could for example be a requirement for dermatological specialty associated to the encounter or prescriber.

#### *Exclusion Criteria*

**Probable other indication for receiving biological therapy.** The general study CED must not be preceded by any diagnosis (or other means of ascertainment) of clinical conditions that could lead to treatment with any of the drugs evaluated in the BRAHMS study e.g., Crohn's disease, ulcerative colitis, suppurative hidradenitis, or inflammatory arthritis. Psoriasis arthritis does not lead to exclusion but is to be adjusted for in the statistical analysis.

The analysis specific cohorts are then created from the general study cohort by applying analysis specific in- and exclusion criteria, which vary across analyses. For the active comparator cohort studies, in- and exclusion criteria are implemented relative to the cohort entry date (CED); for the case-time-control studies, they are implemented relative to the event date for cases and the index dates for controls. In- and exclusion criteria for study specific cohorts are described in **Box 2** and visualized in **Figure 2**.

**Box 2.** In- and exclusion criteria for analysis specific cohorts (may vary across analyses) in the active comparator cohort design and the case-time-control design.

*Inclusion criteria*

**Minimum registry coverage.** Only individuals with a minimum medical and drug coverage of 183 days prior to the cohort entry date (CED) (730 days for cancer) are included in the active comparator cohort studies, whereas 365 days are required in the case-time-control studies to ensure coverage before the first reference date.

**Age.** Only individuals who are 18 years or older on the CED are included in the active comparator cohort studies, whereas a minimum age of 21 is required in the case-time-control studies to ensure that individuals are at least 18 years on the first reference date.

**Non-bionäive.** Only individuals with at least one prior treatment of another biologic than the drug of interest are included in the active comparator studies. A prior treatment must be recorded at least once within 365 days before the CED. Of note, to avoid potential carry-over effect, prior treatment with brodalumab is not allowed when considering CEDs for active comparators.

**At least one period of brodalumab use.** Specific criterion for the case-time-control studies. Only inclusion of individuals in the case-time-control studies who have a period of use of brodalumab within 730 days prior to the event date/index date.

*Exclusion criteria*

**History of outcome.** Individuals with a recording of the outcome (or part of the outcome or history related to the outcome) prior to the CED are excluded.

**Previous use of drug of interest.** Individuals who have been using the drug of interest (evaluated at substance level) prior to the CED are excluded from the active comparator cohort design, e.g., prior users of brodalumab are excluded from the brodalumab treatment group.

*Study drugs*

1  
2  
3 Brodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adult  
4 patients who are candidates for systemic therapy. The recommended dose is 210 mg  
5 administered by subcutaneous injection at weeks 0, 1, and 2 followed by 210 mg every 2 weeks.  
6  
7 Brodalumab is usually administered in a hospital setting or in specialist practice, but patients may  
8 self-inject after careful instruction[20].  
9  
10

11  
12  
13 Comparator drugs used in the active-comparator cohort design include the following:  
14

- 15 1. Inhibitors of IL-12 and IL-23 (ustekinumab, including biosimilars whenever available)
- 16 2. Inhibitors of TNF- $\alpha$  (etanercept and adalimumab, including biosimilars whenever available).
- 17 3. Other inhibitors of cytokine IL-17A (secukinumab and ixekizumab, including biosimilars  
18 whenever available)  
19  
20  
21  
22

23 Similar to brodalumab, comparator drugs are all administered by subcutaneous injection. For  
24 this reason, infliximab is not included among the TNF- $\alpha$  inhibitor study drugs as it is solely  
25 given intravenously. This could introduce selection bias by restricting to hospital-treated  
26 patients. The dosing interval varies from once a week for TNF- $\alpha$  inhibitors to every 12 weeks  
27 for ustekinumab.  
28  
29  
30  
31  
32

### 33 34 35 ***Exposure definition*** 36

37  
38 Episodes covered by treatment with study drugs are created for every individual in the general  
39 study cohort within the individual's eligibility period by assigning a dispensing duration  
40 corresponding to the expected time covered by that dispensing. Dispensing durations of the  
41 same biologic are then combined into continuous treatment episodes if there are no gaps  
42 between them. Finally, overlapping time in treatment episodes of different biologics are resolved  
43 by formally terminating any treatment episode when a treatment episode with another biologic  
44 begins (**Figure 3**). The result is a non-overlapping sequence of treatment episodes for each  
45 individual. At no point in time are persons considered exposed to more than one study drug.  
46  
47 This is in line with the dominating treatment regimen in psoriasis, where biologics are prescribed  
48 as monotherapy or in combination with topical treatments[21,22].  
49  
50  
51  
52  
53  
54

55  
56 Dispensing durations are estimated separately for each biologic at each site using the waiting time  
57 distribution (WTD) method, which is a data-driven approach[23]. The WTD method estimates  
58 the interarrival density function, i.e., the distribution of gap time between dispensings inside a  
59  
60



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

treatment episode for patients in continuous treatment. For this distribution, we will use the time corresponding to the 95<sup>th</sup> percentile as dispensing duration. This approach mitigates challenges resulting from the heterogeneous availability of data on dispensing durations for biologics, such as recordings of dose or days covered, across sites.

**Outcome**

Study outcomes include:

Serious infections, i.e., the composite of serious acute infections and incident serious chronic infections. A serious acute infection is defined as any community-acquired acute bacterial, viral, or fungal infection that is severe enough to lead to hospitalization or death. An incident serious chronic infection is defined as a new infection with tuberculosis, hepatitis B or C, or other severe viral hepatitis infections, or osteomyelitis either leading to hospitalization or treated at outpatient specialist visits.

Suicidal conduct, i.e., the composite of death by suicide or suicide attempt leading to hospitalization or treatment at outpatient visits.

MACE, i.e., the composite of hospital admissions due to acute myocardial infarction, stroke (including ischemic stroke and haemorrhagic stroke but excluding transient ischemic attack), or cardiovascular death in- or outside hospital.

Cancer, i.e., a diagnosis of malignant neoplasms.

The exact definition of these outcomes may vary across sites, according to availability and structure of data.

**Analysis**

*Case-time-control design specifications*

In the case-time-control design, each individual’s exposure status at the index date is compared to four reference dates in the same individual’s past. The index date is the date of the outcome. Control individuals without outcomes are sampled 4:1 by a risk set sampling strategy, matched

by age and sex and assigned an index date identical to their corresponding case. Only cases and controls who have been exposed to brodalumab either at the index date or at least at one of the reference dates contribute to the analysis. An individual is considered exposed to brodalumab at an index- or reference date if they occurred within a brodalumab treatment episode.

Consistent with standard recommendations regarding case-time-control design, a washout interval is interspersed between the index date and the latest of the reference dates to minimize carry over between index and reference dates[17]. We chose a fairly long interval between each index date and reference point, 4 months, to minimize autocorrelation by exposure[24]. The case-time-control design employed is illustrated in **Figure 4**.

Due to the inherently matched nature of this design, conditional logistic regression is used to calculate ORs [15].

#### *Active comparator cohort design specifications*

The active comparator cohort design addresses the pragmatic, clinical question of whether the outcome association is stronger for brodalumab than for comparable drugs, as rates of events are compared between users of brodalumab and users of other biological treatments.

Adaptations of the active comparator cohort design are used to investigate the effects of both new use, ongoing use without restricting to new users, ever use and cumulative duration of use of brodalumab depending on the expected biological mechanism behind a potential association between use of brodalumab and the outcome.

For serious infections and SIB, the potential effect of brodalumab is likely to emerge shortly after initiation and is expected to persist during ongoing exposure. The associations are therefore investigated using the active comparator, new user cohort design as well as the variation hereof adapted to ongoing use without restriction to new users. In the active comparator, new user cohort analysis only incident treatment episodes of the drug of interest are included. That is, individuals are only considered exposed while being treated with the drug of interest for the first time. Subsequent treatment episodes with the same drug do not contribute to the analysis. The analysis adapted to ongoing use without restricting to new users only differs by also allowing subsequent treatment episodes.

For cancer as the outcome, an effect of brodalumab may manifest with some latency, possibly even after termination of treatment. Therefore, the active comparator study adapted to ever use

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

is applied. In this analysis, an individual’s exposure status remains unchanged even if the drug of interest is discontinued or another biologic is initiated. To avoid unduly complicated histories of exposure patterns in this analysis and undue assumptions, the comparison is with all active comparators without making distinctions at substance level or substance group level.

When investigating a potential association with cancer, it is also reasonable to assume a cumulative dose response association, i.e., users with high cumulative doses have higher risk than users with low cumulative doses, all things being equal. A methodological challenge is in the comparative element; to assess whether the cumulative dose-response effect is more pronounced for brodalumab than for its active comparators. For this purpose, we developed an active comparator cohort design, adapted to cumulative exposure effects. We establish running cumulative accounts of exposed person-time from brodalumab treatment episodes as well as running accounts of exposed person-time from treatment episodes of any study biologics, including brodalumab. Only incident treatment episodes with a starting date within an individual’s eligibility period contributes to the analysis (**Figure 5**).

For MACE as the outcome, the underlying biological mechanisms behind a potential association are unknown i.e., neither an immediate effect of ongoing exposure nor a delayed effect of long-term use can be ruled out. Thus, all four variations of the active comparator cohort design are used to investigate a potential association between brodalumab and the risk of MACE.

For the analysis adapted to cumulative exposure effects, a Cox-regression is performed with cumulative exposure to any biologic and to brodalumab included in parallel as time-dependent variables. The potential incremental effect associated with brodalumab cumulative exposure, above and beyond the cumulative exposure to study biologics in general, is estimated by the coefficient for the cumulative dose of brodalumab in that regression. The model allows for concurrent adjustment for other relevant covariates if they are available.

A standard meta-analysis, including country-specific estimates from the main analysis of each outcome is performed for both the active comparator cohort design and the case-time-control design.

**Potential limitations**

The active comparator cohort design is vulnerable to confounding due to differences in patient characteristics between the brodalumab and active comparator groups. This is accounted for in several ways. First, to optimize comparability between users of brodalumab and users of active comparators, only treatment episodes that are incident or preceded by an incident treatment episode within an individual's eligibility period are included. A minimum look-back of 183 days is required to ensure incident use. Also, as brodalumab is considered a second-line treatment, we require all users of comparator drugs to have switched from another biologic anti-psoriatic drug before cohort entry. Finally, in the standard active comparator analyses, measured confounding is addressed by using propensity score matching as the main tool[25]. IPTW (Inverse Probability of Treatment Weighting) are applied in a sensitivity analysis.

In both the active comparator cohort design and the case-time-control design, analyses are performed with and without restriction to individuals without a history of the outcome of interest to limit confounding by indication. Time-dependent confounding by disease activity is handled by adjusting for measures of disease activity and proxies hereof whenever this is possible.

Considerable heterogeneity in the structure, quality, availability (e.g., cause of death) and coding practice across sites is expected. Some of these problems might be mitigated by using a common data model (CDM) and a centralized development of analysis. In addition, there will be validation studies of suicidal conduct in selected regions, albeit no general case validation is planned.

The mapping of exposure status involves critical decisions with an inherent risk of misclassification. This may threaten the validity of both designs. Consequently, the estimation of dispensing durations using the waiting time distribution is subject to several sensitivity analyses.

The range of subgroup-, sensitivity-, and supplementary analyses performed to elucidate potential biases are described in **Supplementary Table 1**.

### ***Data management***

The data infrastructure of the BRAHMS study is based on a distributed database network which applies a CDM designed specifically for the study. The BRAHMS CDM provides a detailed specification of an agreed data structure and codebook, that each site must transform their local

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

register data into. A quality assurance program is used to confirm compliance. The result of data transformation is a locally populated instance of the BRAHMS CDM containing all relevant study data structured identically across sites, but accessible only by the local site. The coordinating site creates analytical programs to be run locally at each site. Only aggregate results from these programs are shared across sites. This strategy is described in the ENCePP Guide on Methodological Standards in Pharmacoepidemiology, in the section on multi-database studies[26].

The heterogeneity of e.g., available data sources, coding practices, and validity of codes across sites is a limitation that necessitates a flexible method of adapting study variable definitions (required codes, settings, number of occurrences, assessment windows, etc.) to the requirement of each site. A component-composite framework is implemented[27,28]. In this framework, each study variable is defined locally as a logical composite of one or more components. Each component is a specification of codes e.g., diagnoses codes or ATC codes, and contextual conditions e.g., “only inpatient contacts”, that records in the CDM must fulfil[27,28].

**Other**

*Study sponsorship: monitoring, audit, quality control and quality assurance*

The study sponsor is the University of Southern Denmark, which undertakes quality assurance. The study is funded by Leo Pharma, the market authorization holder of brodalumab, as part of an EMA mandated Post Authorization Safety Study[29].

*Access to data*

Data will be available for local investigators only. Data extraction and analyses are performed locally, and results are transferred at an aggregate level to SDU. Individual-level data will be unavailable across the other sites and to third parties outside the BRAHMS collaboration.

*Study registration*

The BRAHMS study is registered in the EU - PASS register (reference number EUPAS30280).

## **Ethics and dissemination**

The BRAHMS study is performed in accordance with International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practice guidance[30]. The study is approved by relevant authorities in Denmark, Norway, Sweden, the Netherlands, Germany, and Italy in line with the relevant legislation at each site. The General Data Protective Regulation (GDPR) will be followed, and data confidentiality will be ensured by the distributed network approach to data exchange. The results of the study will be published in peer-reviewed scientific journals and presented at relevant conferences.

## **Patient and public involvement**

Patients and/or the public were not involved in this study.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Discussion**

The BRAHMS study design and innovative data infrastructure serves as an example of how a large multi-database safety study can be conducted by efficiently using data sources and IT, including follow up of patients by record linkage. Through the distributed network methodology, the CDM, and the centralized programming, the risk for breach of data confidentiality is minimal and a high analytical standard is achieved.

The results from the BRAHMS study will be of substantial interest to patients with moderate to severe psoriasis and their treating physicians, irrespective of its findings. If the BRAHMS study reveals associations with any of the outcomes, further regulatory actions would be initiated to limit their impact. If BRAHMS identifies no associations with any of the outcomes, brodalumab can be used confidently at its proper position in the armamentarium of biological anti-psoriatic agents. Treatment failure occurs frequently with biological psoriasis treatment[31], and it is vital to have multiple medications that offers new treatment alternatives when others have failed.

As an important collateral benefit of the study, we build network, experience, methodology and infrastructure which allows for a timely and scientifically rigorous investigation of future safety issues, especially in the area of biologic drug use in psoriasis and other immune mediated inflammatory diseases.

## Author's contribution

Conception and design: MR, PBJ, LSR, JH, AE, KF, KG, DH, UH, ØK, JR, WS, SS, ES, EH, RH, GT, UK, ACR, VB, RG, HS. Writing the article: MR, PBJ, LSR and JH prepared the first draft of the paper. Critical revision of the article: MR, PBJ, LSR, JH, AE, KF, KG, DH, UH, ØK, JR, WS, SS, ES, EH, RH, GT, UK, ACR, VB, RG, HS. Final approval: MR, PBJ, LSR, JH, AE, KF, KG, DH, UH, ØK, JR, WS, SS, ES, EH, RH, GT, UK, ACR, VB, RG, HS. Overall responsibility: MR, PBJ, LSR, JH.

## Funding statement

The current study is funded by LEO Pharma A/S, with funds paid to participating institutions (no personal fees). Award/grant number N/A.

## Competing interest statement

Mette Reilev and Peter Bjødstrup Jensen report participation in research funded by LEO Pharma A/S (no personal fees).

Jesper Hallas reports participation in studies funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, Pfizer, Menarini Pharmaceuticals, and LEO Pharma, all regulator mandated phase IV studies, all with funds paid to the institution (no personal fees). J Hallas has received teaching fees from Atrium.

Henrik Støvring reports participation in research funded by LEO Pharma A/S (no personal fees). He has received personal consulting fees from Bristol-Myers-Squibb, Novartis, Roche, Merck and Pfizer outside the submitted work. He has received teaching fees from Atrium.

Kari Furu and Øystein Karlstad reports participation in research projects funded by Novo Nordisk and LEO Pharma, all regulator mandated phase IV studies, all with funds paid to the institution (no personal fees).

Elisabeth Smits, Emily Holthuis and Ron Herings are employees of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies.

Alexander Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, Horizon Therapeutics, and Janssen Pharmaceuticals.

Ursula Kirchmayer, Alessandro Cesare Rosa, and Valeria Belleudi are employees of the Department of Epidemiology ASL Roma1, Lazio Regional Health Service in Rome, Italy. Our publicly funded department performs epidemiological research and receives grants from public national and international organisations. In case of financial support from private organisations, an ethical code of conduct is signed to guarantee transparency and independence.

Karin Gembert, David Hägg and Johan Reutfors are employees of the Centre for Pharmacoepidemiology of the Karolinska Institutet in Sweden, which receives grants from regulatory authorities, pharmaceutical companies, and contract research organizations for performance of drug safety and drug utilization studies.

Ulrike Haug, Wiebke Schäfer and Sarina Schwarz are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology – BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. Almost exclusively, these are post-authorization safety studies (PASS) requested by health authorities.

Gianluca Trifirò declares participation to advisory boards on topics not related to this paper and sponsored by the following pharmaceutical companies in the last two years: Eli Lilly; Sanofi; Amgen; Novo Nordisk; Sobi; Gilead; Celgene; Daikii Sankyo.

RG is employed by ARS, a public research center participating in pharmacoepidemiology studies funded by public or private institutions and compliant with the ENCePP Code of Conduct. The budget of ARS is partially sustained by such studies.

## References

- 1 Armstrong AW, Mehta MD, Schupp CW, *et al.* Psoriasis Prevalence in Adults in the United States. *JAMA Dermatol* 2021;**157**:940–6. doi:10.1001/jamadermatol.2021.2007
- 2 Parisi R, Iskandar IYK, Kontopantelis E, *et al.* National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ* 2020;**369**:m1590. doi:10.1136/bmj.m1590
- 3 Levin EC, Gupta R, Brown G, *et al.* Biologic fatigue in psoriasis. *J Dermatol Treat* 2014;**25**:78–82. doi:10.3109/09546634.2013.826341
- 4 Lebwohl M, Strober B, Menter A, *et al.* Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *N Engl J Med* 2015;**373**:1318–28. doi:10.1056/NEJMoa1503824
- 5 Papp KA, Leonardi C, Menter A, *et al.* Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. *N Engl J Med* 2012;**366**:1181–9. doi:10.1056/NEJMoa1109017
- 6 Papp K, Menter A, Leonardi C, *et al.* Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). *Br J Dermatol* 2020;**183**:1037–48. doi:10.1111/bjd.19132
- 7 Hansel TT, Kropshofer H, Singer T, *et al.* The safety and side effects of monoclonal antibodies. *Nat Rev Drug Discov* 2010;**9**:325–38. doi:10.1038/nrd3003
- 8 Puel A, Cypowyj S, Maródi L, *et al.* Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. *Curr Opin Allergy Clin Immunol* 2012;**12**:616–22. doi:10.1097/ACI.0b013e328358cc0b
- 9 Liang SE, Cohen JM, Ho RS. Psoriasis and suicidality: A review of the literature. *Dermatol Ther* 2019;**32**:e12771. doi:10.1111/dth.12771
- 10 Pompili M, Bonanni L, Gualtieri F, *et al.* Suicidal risks with psoriasis and atopic dermatitis: Systematic review and meta-analysis. *J Psychosom Res* 2021;**141**:110347. doi:10.1016/j.jpsychores.2020.110347
- 11 Lebwohl MG, Papp KA, Marangell LB, *et al.* Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. *J Am Acad Dermatol* Published Online First: October 2017. doi:10.1016/j.jaad.2017.08.024
- 12 Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. *Arch Dermatol Res* 2017;**309**:225–8. doi:10.1007/s00403-016-1712-1
- 13 Torres T, Raposo I, Selores M. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk? *Am J Clin Dermatol* 2016;**17**:107–12. doi:10.1007/s40257-015-0166-0
- 14 Peleva E, Exton LS, Kelley K, *et al.* Risk of Cancer in Patients with Psoriasis on Biologic Therapies: A Systematic Review. *Br J Dermatol* Published Online First: 19 July 2017. doi:10.1111/bjd.15830
- 15 Suissa S. The case-time-control design. *Epidemiol Camb Mass* 1995;**6**:248–53. doi:10.1097/00001648-199505000-00010

16 Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Curr Epidemiol Rep* 2015;**2**:221–8. doi:10.1007/s40471-015-0053-5

17 Cadarette SM, Maclure M, Delaney JAC, *et al.* Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. *Pharmacoepidemiol Drug Saf* 2021;**30**:671–84. doi:10.1002/pds.5227

18 Hallas J, Pottegård A, Wang S, *et al.* Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. *Am J Epidemiol* 2016;**184**:761–9. doi:10.1093/aje/kww079

19 Bykov K, Wang SV, Hallas J, *et al.* Bias in case-crossover studies of medications due to persistent use: A simulation study. *Pharmacoepidemiol Drug Saf* 2020;**29**:1079–85. doi:10.1002/pds.5031

20 kyntheum - Summary of product characteristics.  
[https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf) (accessed 29 Mar 2022).

21 Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykiewicz NM, *et al.* Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. *Dermatol Ther* 2021;**11**:2107–21. doi:10.1007/s13555-021-00616-7

22 Menter A, Strober BE, Kaplan DH, *et al.* Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol* 2019;**80**:1029–72. doi:10.1016/j.jaad.2018.11.057

23 Støvring H, Pottegård A, Hallas J. Determining prescription durations based on the parametric waiting time distribution. *Pharmacoepidemiol Drug Saf* 2016;**25**:1451–9. doi:10.1002/pds.4114

24 Jensen AKG, Gerds TA, Weeke P, *et al.* On the validity of the case-time-control design for autocorrelated exposure histories. *Epidemiol Camb Mass* 2014;**25**:110–3. doi:10.1097/EDE.0000000000000001

25 Stürmer T, Wyss R, Glynn RJ, *et al.* Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. *J Intern Med* 2014;**275**:570–80. doi:10.1111/joim.12197

26 1.ENCePPMethodsGuideRev.9.pdf.  
[https://www.encepp.eu/standards\\_and\\_guidances/documents/1.ENCePPMethodsGuideRev.9.pdf](https://www.encepp.eu/standards_and_guidances/documents/1.ENCePPMethodsGuideRev.9.pdf) (accessed 8 Mar 2022).

27 Roberto G, Leal I, Sattar N, *et al.* Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. *PloS One* 2016;**11**:e0160648. doi:10.1371/journal.pone.0160648


28 Gini R, Dodd CN, Bollaerts K, *et al.* Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project. *Vaccine* 2020;**38** Suppl 2:B56–64. doi:10.1016/j.vaccine.2019.07.045

29 BRAHMS study ENCePP registration.  
<https://www.encepp.eu/encepp/viewResource.htm?id=43504> (accessed 21 Apr 2022).

- 1  
2  
3 30 Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for  
4 good pharmacoepidemiology practice (GPP): Guidelines for good pharmacoepidemiology  
5 practice. *Pharmacoepidemiol Drug Saf* 2016;**25**:2–10. doi:10.1002/pds.3891  
6  
7  
8 31 Ai M, R G. Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative  
9 Meta-Analysis. *Front Med* 2021;**7**. doi:10.3389/fmed.2020.625755  
10  
11  
12


### 13 Acknowledgements

14  
15  
16 None  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 1.** Design diagram for the building of the general study cohort. Light blue: inclusion criteria; Red: exclusion criteria; Grey: Eligibility period. The cohort entry date must lie within the study period, and it must be the earliest possible date that fulfils all inclusion and exclusion criteria.

A)




B)




**Figure 2.** Design diagrams for inclusion- and exclusion criteria implemented in A) the active comparator cohort studies and B) the case-time-control studies. Light blue: inclusion criteria; Red: exclusion criteria; Grey: follow-up window.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




**Figure 3.** Illustration of the process of creating treatment episodes for a person in the general study cohort. Each color in the top 4 panels represent a specific biologic substance used in the treatment of psoriasis. Infliximab (yellow) is not a study drug but dispensing of Infliximab are included in the following steps anyway. Circles represent dispensing timepoints and lines represent dispensing duration. (1) All dispensing of biologics used to treat psoriasis within the eligibility window are identified. A dispensing duration is added to each dispensing. (2) Within each drug, overlapping durations are combined. (3) Between drugs, non-overlapping episodes are created by always truncating a previous episode when it is interrupted by a dispensing by another drug. (4) Episodes for non-study biologics are removed. The result is 6 treatment episodes for 3 different study drugs. (5) Episodes are also created on substance group level, by collapsing substance level episodes by their substance group. This results in 4 treatment episodes for 2 different substance groups.



**Figure 4.** In the case-time-control design, exposure status is compared on event-/index date and reference dates. The first four individuals are discordant (i.e., they have periods of both non-use and use of brodalumab) while individual number five is concordant (i.e., has the same exposure status in all windows, either consistently use or consistently non-use of brodalumab), and therefore does not contribute to the analysis. The black dots represent the date of the outcome event (for cases) or the index date (for controls), while the black arrows mark the reference dates. The shaded areas indicate the time exposed to brodalumab.





**Figure 5.** Methods of the cumulative comparative cohort design. The graph illustrates the accumulation of doses during the study period of an individual who is given three different drugs: TNF- $\alpha$  inhibitors, brodalumab, and IL-12 and IL-23 inhibitors. For each time point, a running account of the cumulative dosing of each drug is worked up. For example, when the IL-12 and IL-23 inhibitor is initiated, the individual has a cumulative dose of TNF- $\alpha$  inhibitors, stemming from the first interval, and a cumulative dose of brodalumab stemming from the second interval. As the third interval passes, the individual gradually increases the cumulative dose of IL-12 and IL-23 inhibitor while the cumulative doses for brodalumab and TNF- $\alpha$  inhibitors remain constant. At no point in time during exposure the cumulative amount of these three drugs is identical to another point in time. In the analytic dataset, all non-brodalumab biologics are to be grouped together, and a running account of cumulative brodalumab and cumulative non-brodalumab biologics are to be calculated. The metric used for the cumulative analysis is cumulative time treated, rather than a cumulative dose in mg or defined daily doses. The shaded boxes illustrate the lag-time with respect to any biologic exposure (i.e., the time interval where any occurrence of a cancer cannot be expected to be caused by time spent in a given cumulative exposure).

## Supplementary Material

**Supplementary Table 1.** An overview of main-, supplementary- and sensitivity analyses of the association between use of brodalumab and suicide attempts, serious infections, MACE and cancer. Each bullet under *supplementary and sensitivity analyses* describes how the analysis differs from the main analysis.

|  | Case-time-control design  | Active-comparator cohort design   |
|--|---|---|
| <i>Suicide attempts</i>  |   |   |
| <b>Main analyses</b>   | <p>Event/index date: First occurrence of the composite of fatal and non-fatal suicide attempts during eligibility period for cases and corresponding date for controls</p> <p>Study population: Restricted to brodalumab users without a history of psychiatric disease, suicide attempt, use of anti-depressants or use of lithium</p> <p>Exposure: Brodalumab</p> <p>Time intervals: 4 months</p> <p>Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution</p> <p>Adjustment for time varying activity</p> <p>No comparison to contrasting use</p> | <p>Cohort entry: Start of incident treatment episode of drug of interest</p> <p>Study population: Restricted to individuals without a history of psychiatric disease, suicide attempt, use of anti-depressants or use of lithium</p> <p>Outcome: First occurrence of the composite of fatal and non-fatal suicide attempts during eligibility period</p> <p>Exposure: Brodalumab vs. TNF-alpha inhibitors, IL-12 and IL-23, other inhibitors of IL-17(substance group level)</p> <p>Confounder adjustment: 1:4 propensity score matching with replacement</p> <p>Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution</p> |
| <b>Supplementary and sensitivity analyses</b><br>(Differs from main analysis by) | <ol style="list-style-type: none"> <li>1. Subgroup analysis with comparison to contrasting use</li> <li>2. Study population: No restriction by psychiatric history</li> <li>3. Time intervals: 2 months</li> <li>4. Time intervals: 6 months</li> <li>5. No adjustment for time varying activity</li> <li>6. Outcome: Death by suicide</li> <li>7. Outcome: First suicide attempt during eligibility period</li> </ol>  | <ol style="list-style-type: none"> <li>1. Study population: No restriction by psychiatric history</li> <li>2. Cohort entry: Not restricted to incident treatment episode</li> <li>3. Confounder adjustment: IPTW</li> <li>4. Exposure: Brodalumab vs. ustekinumab, etanercept, adalimumab, secukinumab, and ixekizumab (substance level)</li> <li>5. Outcome: Death by suicide</li> <li>6. Outcome: First suicide attempt during eligibility period</li> </ol>  |

|   |  |  |
|---|--|--|
| 1 |  |  |
| 2 | 8. Method of dispensing duration estimation: WTD, 90 <sup>th</sup> percentile, | 7. Method of dispensing duration estimation: WTD, 90 <sup>th</sup> percentile, |
| 3 | log-normal backward recurrence distribution                                    | log-normal backward recurrence distribution                                    |
| 4 |  |  |
| 5 | 9. Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, | 8. Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, |
| 6 | Weibull distribution   | Weibull distribution   |
| 7 |  |  |
| 8 |  |  |
| 9 |  |  |

Serious infections

|    |  |  |
|----|--|--|
| 11 |  |  |
| 12 | <b>Main analyses</b>   |  |
| 13 | Event/index date: First occurrence of a serious infection i.e., the              | Cohort entry: Start of incident treatment episode of drug of interest            |
| 14 | composite of acute serious infections and chronic infections, during             | Study population: Restricted to individuals without a history of                 |
| 15 | the eligibility period   | chronic infections   |
| 16 |  | Outcome: first occurrence of a serious infection i.e., the composite of          |
| 17 | Study population: Restricted to brodalumab users without a history of            | acute serious infections and chronic infections, during the eligibility          |
| 18 | chronic infections   | period   |
| 19 | Exposure: brodalumab   | Exposure: Brodalumab vs. TNF-alpha inhibitors, IL-12 and IL-23,                  |
| 20 | Time intervals: 4 months   | other inhibitors of IL-17(substance group level)                                 |
| 21 | Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, log- | Confounder adjustment: 1:4 propensity score matching with                        |
| 22 | normal backward recurrence distribution  | replacement  |
| 23 | Adjustment for time varying activity   | Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, log- |
| 24 | No comparison to contrasting use   | normal backward recurrence distribution  |
| 25 |  |  |
| 26 |  |  |
| 27 |  |  |
| 28 |  |  |
| 29 |  |  |

|    |                             |   |
|----|-----------------------------|---|
| 30 |                             |   |
| 31 | <b>Supplementary and</b>    |   |
| 32 | <b>sensitivity analyses</b> |   |
| 33 | (Differs from main          | 1. Study population: Restricted to individuals without a history of     |
| 34 | analysis by)                | either acute serious infection or chronic infections                    |
| 35 |                             | 2. Cohort entry: Not restricted to incident treatment episode           |
| 36 |                             | 3. Confounder adjustment: IPTW  |
| 37 |                             | 4. Exposure: Brodalumab vs. ustekinumab, etanercept, adalimumab,        |
| 38 |                             | secukinumab, and ixekizumab (substance level)                           |
| 39 |                             | 5. Outcome: First acute serious infection during the eligibility period |
| 40 |                             |   |
| 41 |                             |   |
| 42 |                             |   |
| 43 |                             |   |
| 44 |                             |   |
| 45 |                             |   |
| 46 |                             |   |

7. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

8. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

6. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

7. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

## MACE

### Main analyses

Event/index date: First occurrence of MACE during eligibility period

Study population: All brodalumab users. No restriction by outcome

Exposure: Brodalumab

Time intervals: 4 months

Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution

Adjustment for time varying activity

No comparison to contrasting use

Cohort entry: Start of incident treatment episode of drug of interest

Study population: No restriction by history MACE

Outcome: first occurrence of a MACE during the eligibility period

Exposure: Brodalumab vs. TNF-alpha inhibitors, IL-12 and IL-23, other inhibitors of IL-17(substance group level)

Confounder adjustment: 1:4 propensity score matching with replacement

Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution

### Supplementary and sensitivity analyses

(Differs from main analysis by)

1. Subgroup analysis with comparison to contrasting use

2. Study population: Restricted to brodalumab users without a history of MACE, acute coronary syndrome, or transitory ischemic attack

3. Time intervals: 2 months

4. Time intervals: 6 months

5. No adjustment for time varying activity

6. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

7. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

1. Study population: Restricted to individuals without a history of MACE, acute coronary syndrome, or transitory ischemic attack

2. Cohort entry: Not restricted to incident treatment episode

3. Confounder adjustment: IPTW

4. Exposure: Brodalumab vs. ustekinumab, etanercept, adalimumab, secukinumab, and ixekizumab (substance level)

5. Exposure: Ever use of brodalumab vs. any active comparator

6. Cumulative use of brodalumab vs. any biologics used in the treatment of psoriasis

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

7. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

8. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

---

*Cancer*

|   |                |   |
|---|----------------|---|
| <b>Main analyses</b>                          | Not applicable | Cohort entry: Start of any treatment episode but restricted to episodes that are incident or follow an incident episode within eligibility period |
|   |                | Study population: Restricted to individuals without a history of cancer   |
|   |                | Outcome: First cancer diagnosis ever  |
|   |                | Exposure: Ever use of brodalumab vs. any active comparator  |
|   |                | Lag-time: 12 months   |
|   |                | Confounder adjustment: 1:4 propensity score matching with replacement   |
|   |                | Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, log-normal backward recurrence distribution                           |
| <b>Supplementary and sensitivity analyses</b> |                | 1. Study population: No restriction by cancer history   |
| (Differs from main analysis by)               |                | 2. Lag-time: 6 months   |
|   |                | 3. Lag-time: 24 months  |
|   |                | 4. Outcome: first cancer diagnosis ever excl. NMSC  |
|   |                | 5. Confounder adjustment: IPTW  |
|   |                | 6. Cumulative use of brodalumab vs. any biologics used in the treatment of psoriasis  |
|   |                | 7. Method of dispensing duration estimation: WTD, 90 <sup>th</sup> percentile, log-normal backward recurrence distribution                        |

---

8. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile,  
Weibull distribution

---

WTD: Waiting time distribution; IPTW: Inverse probability of treatment weighting; TNF: Tumor necrosis factor; MACE: Major adverse cardiac events;  
NMSC: Non-melanoma skin cancer

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only

# BMJ Open

## Methodology of the BRodalumab Assessment of Hazards: A Multicentre observational Safety (BRAHMS) study

|                                 |  |
|---------------------------------|--|
| Journal:                        | <i>BMJ Open</i>  |
| Manuscript ID                   | bmjopen-2022-066057.R1   |
| Article Type:                   | Protocol   |
| Date Submitted by the Author:   | 11-Jan-2023  |
| Complete List of Authors:       | <p>Reilev, Mette; University of Southern Denmark, Clinical Pharmacology, Pharmacy and Environmental Medicine<br/> Jensen, Peter Bjødstrup; University of Southern Denmark, Clinical Pharmacology, Pharmacy and Environmental Medicine<br/> Ranch, Lise Skov; LEO Pharma A/S, Biostatistics and Pharmacoepidemiology<br/> Egeberg, A; Gentofte Hospital, Department of Dermatology and Allergy<br/> Furu, Kari; Norwegian Institute of Public Health, Department of Pharmacoepidemiology<br/> Gembert, Karin; Karolinska Institute<br/> Hagg, David; Karolinska Institute<br/> Haug, Ulrike; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Clinical Epidemiology; High-Profile Research Area Health Sciences, University of Bremen<br/> Karlstad, Øystein; Nasjonalt folkehelseinstitutt, Department of Chronic Diseases<br/> Reutfors, Johan; Karolinska Institute<br/> Schäfer, Wiebke; Leibniz Institute for Prevention Research and Epidemiology – BIPS, Clinical Epidemiology<br/> Schwartz, Sarina; 6. Leibniz-Institute for Prevention Research and Epidemiology-BIPS<br/> Smits, Elisabeth; PHARMO Institute for Drug Outcomes Research<br/> Holthius, Emily; PHARMO Institute for Drug Outcomes Research<br/> Herings, Ron; PHARMO Institute for Drug Outcomes Research; Vrije Universiteit Amsterdam<br/> Trifirò, Gianluca; University of Verona, Department of Diagnostics and Public Health<br/> Kirchmayer, Ursula; Department of Epidemiology, Regional Health Service, Lazio Region.<br/> Rosa, Alessandro Cesare; Lazio Regional Health Service, Department of Epidemiology<br/> Belleudi, Valeria; Department of Epidemiology, Lazio Regional Health Service; ASL Roma 1<br/> Gini, Rosa; Agenzia regionale di sanità della Toscana, Epidemiology Unit; Erasmus Medical Center, Medical Informatics<br/> Støvring, Henrik; University of Southern Denmark, Clinical Pharmacology, Pharmacy and Environmental Medicine<br/> Hallas, Jesper; University of Southern Denmark, Clinical Pharmacology</p> |
| <b>Primary Subject Heading</b>: | Dermatology  |



|                            |   |
|----------------------------|---|
| Secondary Subject Heading: | Pharmacology and therapeutics   |
| Keywords:                  | Psoriasis < DERMATOLOGY, Adverse events < THERAPEUTICS, INFECTIOUS DISEASES, CARDIOLOGY, Suicide & self-harm < PSYCHIATRY, ONCOLOGY |
|                            |   |

SCHOLARONE™  
Manuscripts

Methodology of the BRodalumab Assessment of Hazards: A Multicentre observational Safety  
(BRAHMS) study

Target journal: BMJ Open, Protocol manuscript

Authors: Mette Reilev<sup>1</sup>, Peter Bjødstrup Jensen<sup>1</sup>, Lise Skov Ranch<sup>2</sup>, Alexander Egeberg<sup>3</sup>, Kari Furu<sup>4</sup>, Karin Gembert<sup>5</sup>, David Hägg<sup>5</sup>, Ulrike Haug<sup>6,7</sup>, Øystein Karlstad<sup>4</sup>, Johan Reutfors<sup>5</sup>, Wiebke Schäfer<sup>6</sup>, Sarina Schwartz<sup>6</sup>, Elisabeth Smits<sup>8</sup>, Emily Holthius<sup>8</sup>, Ron Herings<sup>8,9</sup>, Gianluca Trifirò<sup>10</sup>, Ursula Kirchmayer<sup>11</sup>, Alessandro Cesare Rosa<sup>11</sup>, Valeria Belleudi<sup>11</sup>, Rosa Gini<sup>12</sup>, Henrik Støvring<sup>1</sup>, Jesper Hallas<sup>1</sup> on behalf of the BRAHMS study group

Affiliations:

1. Clinical Pharmacology, Pharmacy and Environmental Medicine, Department of Public Health, University of Southern Denmark
2. Biostatistics and Pharmacoepidemiology, Medical Sciences, LEO Pharma A/S, Denmark
3. Copenhagen University Hospital Bispebjerg, Denmark.
4. Department of Chronic Diseases, Norwegian Institute of Public Health, Norway
5. Karolinska Institute, Sweden
6. Leibniz-Institute for Prevention Research and Epidemiology-BIPS, Germany
7. Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany
8. PHARMO Institute for Drug Outcomes Research, Utrecht, Netherlands
9. Amsterdam UMC, Vrije Universiteit Amsterdam, Epidemiology and Data Science, Amsterdam, Netherlands
10. Department of Diagnostics and Public Health, University of Verona, Italy
11. Department of Epidemiology, ASL Roma 1, Lazio Regional Health Service, Italy
12. Agenzia Regionale di Sanità, Tuscany, Italy

Word count: Abstract: 335; Text: 3549 excluding Boxes 1 and 2

Correspondence:

Mette Reilev  
Clinical Pharmacology, Pharmacy and Environmental Medicine  
University of Southern Denmark  
JB Winslows Vej 19,2, 5000 Odense C  
mreilev@health.sdu.dk

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Abstract**

*Introduction*

Safe and effective pharmacological treatment is of paramount importance for treating severe psoriasis. Brodalumab, a monoclonal antibody against interleukin (IL) 17 receptor A, was granted marketing authorization in the EU in 2017. The European Medicines Agency requested a post-authorization safety study of brodalumab to address potential safety issues raised during drug development regarding major adverse cardiovascular events (MACE), suicidal conduct, cancer and serious infections.

*Methods and analysis*

BRAHMS is a multicentre observational safety study of brodalumab running from 2017-2029 using population-based healthcare databases from Denmark, Sweden, Norway, Netherlands, Germany and 3 different centres in Italy. A distributed database network approach is used, such that only aggregate data are exchanged between sites.

Two types of designs are used: a case-time-control design to study acute effects of transient treatment and a variation of the new user active comparator design to study the effects of transient or chronic treatment. As comparators, inhibitors of TNF- $\alpha$ , inhibitors of IL-12 and IL-23, and other inhibitors of cytokine IL-17A are included.

In the self-controlled case-time-control design, the risk of developing the outcome of interest during periods of brodalumab use is compared within individuals to the risk in periods without use.

In the active comparator cohort design, new users of brodalumab are identified and matched to new users of active comparators. Potential baseline confounders are adjusted for by using propensity score modelling. For outcomes that potentially require large cumulative exposure, an adapted active comparator design has been developed.

*Ethics and dissemination*

The study is approved by relevant authorities in Denmark, Norway, Sweden, the Netherlands, Germany, and Italy in line with the relevant legislation at each site. Data confidentiality is secured by the distributed network approach. Results will be published in peer-reviewed journals.

### *Study registration*

The BRAHMS study is registered in the EU - PASS register (EUPAS30280).

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Strengths and limitations of this study**

- An important strength of the BRAHMS study is the establishment of a collaboration across 6 European countries with data sources covering approximately 50 million people thus allowing investigation of potential safety issues related to use of brodalumab with best achievable statistical precision.
- The BRAHMS study uses multiple designs, applying both the self-controlled, case-time-control design and variations of the active comparator cohort design, thereby also accounting for diverse biological mechanisms behind potential associations and for unique strengths and limitations in each design.
- To mitigate heterogeneity of data sources and coding practices across participating countries, a comprehensive infrastructure has been built including a BRAHMS common data model and a component-composite framework for study variable definitions.
- As an important collateral benefit of the study, we build network, experience, methodology and infrastructure, which allows for a timely and scientifically rigorous investigation of future safety issues, especially in the area of biologic drug use in psoriasis and other immune mediated inflammatory diseases.

## Introduction

Psoriasis is a chronic immune mediated inflammatory skin disease affecting 2 to 3% of adults in western countries[1,2]. Safe and efficacious pharmacological treatments of moderate to severe psoriasis is important to improve quality of life and prevent serious comorbidities in these patients.

An increasing number of biological therapies for the treatment of moderate to severe psoriasis have become available over the last two decades. The patients can profit from this as treatment switches between approved drugs are often needed due to lack of response, tolerability issues, or treatment fatigue[3]. Brodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adults and was granted Marketing Authorization in the EU in 2017. It is a fully human immunomodulatory monoclonal antibody that binds to human interleukin 17 receptor A (IL17 A).

The safety of brodalumab has been investigated in clinical trials including the two pivotal phase III clinical trials AMAGINE-2 and AMAGINE-3[4–6]. In the regulatory processing of the marketing authorisation, specific aspects of long-term safety were agreed to be further investigated as part of the risk management plan for brodalumab. This included the risk of serious infections, suicidal ideation and behaviour, major adverse cardiac event (MACE) and malignancies. The concern for serious infections, MACE and cancer are shared by other biologics approved for the treatment of immune mediated inflammatory diseases and originate from the products' immunomodulatory activity[7]. As brodalumab binds to IL-17 A, the role of IL-17 and the correspondent IL-17 RA in the host defence against bacterial and fungal infections prompts for investigation of the risk of infections in brodalumab treated patients[8]. Some instances of suicidal conduct were observed during the development program[4], but due to the rarity of these events, trial data were inconclusive as to whether brodalumab treated individuals had an excess risk. Psychiatric comorbidity, including suicidality, is well known in psoriasis patients[9,10], and a potential association between suicidal conduct and brodalumab is not substantiated by any known underlying biological mechanism[11]. Psoriasis patients have an increased risk of cardiovascular events[12]. However, the impact of treatment with systemic biologics on the general cardiovascular comorbidity in psoriasis patients is debated[13] and no specific evidence exists for brodalumab. While the results from most studies of the risk of malignancies in psoriasis patients treated with systemic biologics are reassuring, evidence from long-term studies is limited[14]. These risks are therefore to be investigated in a post-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

authorization safety study i.e., the BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study.

**Methods and analysis**

The BRAHMS study is a European multinational observational study using electronic healthcare data covering the period from the first authorization date of brodalumab in Europe (July 2017) until the extraction of the final dataset in 2029. The study intends to evaluate a potential excess risk of serious infections, suicidal conduct (including death by suicide and suicide attempt), MACE, and cancer associated with brodalumab treatment in patients with psoriasis by applying the case-time-control design and variations of the active comparator cohort design adapted to new use, current use, ever-use and high cumulative use.

***Data sources***

The BRAHMS study is conducted in a collaboration between research groups from Denmark (University of Southern Denmark), Sweden (Karolinska Institute), Norway (Norwegian Institute of Public Health), Germany (Leibniz Institute for Prevention Research and Epidemiology - BIPS), the Netherlands (PHARMO Database Network), and Italy (Tuscany (Agenzia Regionale di Sanità), Caserta local health unit (University of Verona), and Lazio (Lazio Regional Health Service)). **Table 1** provides an overview of local population-based electronic healthcare databases included in the study.

**Table 1.** Overview of data sources from each participating site.

|   | <b>Denmark</b>                   | <b>Sweden</b>                        | <b>Norway</b>  | <b>Netherlands</b> | <b>Germany</b>      | <b>Tuscany</b>                   | <b>Caserta</b>               | <b>Lazio</b>                   |
|---|----------------------------------|--------------------------------------|--|--------------------|---------------------|----------------------------------|------------------------------|--------------------------------|
| Individuals covered (% of country pop)                                | 5.7 mill<br>(100%)               | 10 mill<br>(100%)                    | 5.2 mill<br>(100%)   | 4 mill<br>(25%)    | 20 mill<br>(25%)    | 3.6 mill<br>(6%)                 | 1.1 mill<br>(1.8%)           | 5.7 mill<br>(9.5%)             |
| Data source name / data owner   | The Danish Health Data Authority | National Board of Health and Welfare | Norwegian Health and socioeconomic data authorities <sup>4</sup> | PHARMO             | GePaRD <sup>5</sup> | Tuscany regional claims database | Caserta LHU claims databases | Lazio regional claims database |
| <b>Included data types / settings</b>                                 |                                  |                                      |  |                    |                     |                                  |                              |                                |
| Inpatient hospital care   | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Outpatient hospital care  | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes <sup>6</sup>    | No                               | No                           | No                             |
| Emergency room care   | Yes                              | Yes                                  | Yes  | No                 | Yes <sup>7</sup>    | Yes                              | Yes                          | Yes                            |
| Non-hospital specialist care  | No                               | No                                   | Yes  | No                 | Yes                 | No                               | No                           | No                             |
| General practice care   | No                               | No                                   | Yes  | Yes <sup>1</sup>   | No                  | No                               | No                           | No                             |
| Inpatient drug dispensings  | Yes <sup>2</sup>                 | No                                   | Yes  | Yes <sup>1</sup>   | Yes <sup>2</sup>    | No                               | No                           | No                             |
| Outpatient pharmacy dispensed prescription drugs                      | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Civil registration data   | Yes                              | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Cancer register   | Yes                              | Yes                                  | Yes  | No                 | No                  | No                               | No                           | No                             |
| Causes of death register  | Yes                              | Yes                                  | Yes  | No                 | No                  | Yes                              | Yes                          | Yes                            |
| Socio-economy   | No                               | Yes                                  | Yes  | Yes <sup>1</sup>   | Yes                 | Yes                              | Yes                          | Yes                            |
| Pathology register  | No                               | No                                   | No   | No                 | No                  | No                               | No                           | No                             |
| Exemption from copayment register (Italy)                             | No                               | No                                   | No   | No                 | No                  | Yes                              | Yes                          | Yes                            |
| Data availability prior to start of study period <sup>3</sup> (Years) | 15+                              | 12+                                  | 10+  | 15+                | 10-15               | 10+                              | 10+                          | 10+                            |
| <b>Coding systems used</b>  |                                  |                                      |  |                    |                     |                                  |                              |                                |



|            |                       |                       |                 |                        |        |         |         |         |
|------------|-----------------------|-----------------------|-----------------|------------------------|--------|---------|---------|---------|
| Diagnoses  | ICD10                 | ICD10                 | ICD10, ICPC-2   | ICD10, ICD9-CM, ICPC-2 | ICD10  | ICD9-CM | ICD9-CM | ICD9-CM |
| Medication | ATC                   | ATC                   | ATC             | ATC                    | ATC    | ATC     | ATC     | ATC     |
| Procedures | Nomesco (SKS), Custom | Nomesco (KVÅ), Custom | Nomesco, Custom | Custom                 | Custom | ICD9-CM | ICD9-CM | ICD9-CM |

<sup>1</sup> Data collection periods, catchment area and overlap between PHARMO data sources differ

<sup>2</sup> Possible to identify some drugs dispensings such as biologics from procedure codes with limited dosing information

<sup>3</sup> Covered by at least drug dispensing and inpatient hospital data

<sup>4</sup> Linked nationwide data from different register holders in Norway

<sup>5</sup> Based on claims data from 4 German statutory health insurance providers

<sup>6</sup> Excluding endoscopic and surgical procedures

<sup>7</sup> Cannot be distinguished from other hospital care

ICD10: International Classification of Disease 10<sup>th</sup> revision; ICD9-CM: Internation Classification of Disease-9<sup>th</sup> Revision – Clinical Modification; ICPC: International Classification of Primary Care; ATC: Anatomical Therapeutic Classification; Nomesco: Nordic classification of surgical procedures

Common to all collaborating sites is the availability of inpatient hospital data or hospital discharge diagnoses as well as pharmacy claims data with at least 10 years of coverage leading up to study start. Other relevant data sources such as outpatient and primary care data are included but may differ between sites in terms of availability or level of coverage. Linkage between data sources is possible within each site through unique and pseudonymized person identifiers. Depending on the site, local clinical data are encoded using either the ICD-9-CM, ICD-10 or ICPC-2 (primary care) classifications. The ATC classification is generally used to code drug dispensing at all sites. Since dispensing, registration and coding practices for biologics differ by country, some sites will also use procedure codes to identify these dispensing from hospital data. In total, the participating sites have access to data covering a population of approximately 50 million people from 6 European Countries.

### ***Study design***

A major challenge of the BRAHMS study is the inherently increased risk of comorbidities, such as psychiatric and cardiovascular diseases, among psoriasis patients relative to the background population, which may induce confounding by indication. For example, rates of suicidal acts are 42% higher in this patient population than in healthy individuals[10]. To mitigate unmeasured confounding by underlying psoriasis severity, two designs are used; a self-controlled, case-time-control design[15] and variations of an active comparator cohort design[16].

The case-time-control design is appropriate in studies of a transient effect of ongoing exposure related to an abrupt outcome, e.g., in the analysis of suicidal conduct, where a potential risk hereof is expected to increase directly after initiation of the drug and fade immediately after discontinuation. The choice of the case-time-control design among the self-controlled designs was motivated by the fact that some of the outcomes carry a high mortality, which invalidates the bidirectional self-controlled designs, such as the self-controlled case series or symmetry design[17]. In addition, exposure to a given biologic is likely to be chronic, which in a classic case-crossover design would induce persistent user bias[18]. The case-time-control design has been shown to adjust for persistent user bias[19].

To address the diverse nature of the outcomes, we use variations of the active comparator cohort design. From a biological reasoning, a serious infection is likely to be a short-term outcome of brodalumab exposure that can be investigated by employing the new user, active

comparator cohort design. Cancer, on the other hand, is more likely to be caused by a cumulative effect. Hence, neither the case-time-control design nor the new user, active comparator cohort design is suitable to investigate the association of brodalumab use and cancer. Instead, we employ an ever-user approach of the active comparator cohort design and we have developed a comparative design, which is specifically adapted to analysis of cumulative exposures (see below). An overview of the designs employed for each of the outcomes is shown in **Table 2**. Specifications of each design is detailed under “Analysis”.

**Table 2.** Overview of design choices for the Brodalumab Assessment of Hazards; a Multinational Safety (BRAHMS) study. See text for specifications.

|   | Serious infections | Suicidal conduct | MACE | Cancer |
|---|--------------------|------------------|------|--------|
| New use, comparative cohort design        | X                  | X                | X    |        |
| Current use, comparative cohort design    | X                  | X                | X    |        |
| Ever-use, comparative cohort design       |                    |                  | X    | X      |
| Cumulative use, comparative cohort design |                    |                  | X    | X      |
| Case-time-control design                  | X                  | X                | X    |        |

**Study cohorts**

For the wide range of analyses in the BRAHMS study, different study cohorts are created in a two step-process; the first step is the creation of a general study cohort while the second step is the creation of analysis specific cohorts.

Individuals enter the general study cohort on the date of the earliest recording within the study period of a biologic used in the treatment of psoriasis. Individuals are censored if another probable indication for receiving biological therapy is registered, if two or more biologics are registered on the same date, in case of loss of data coverage, death, or end of study period. This step creates an eligibility period for every included individual during which any occurring

treatment episode and outcome may contribute to a specific analysis. Inclusion- and exclusion criteria for the general study cohort are described in **Box 1** and visualized in **Figure 1**.

**Box 1.** Inclusion- and exclusion criteria for the general study cohort. Due to data source heterogeneity, site-specific adaptations are allowed.

#### *Inclusion Criteria*

**Probable psoriasis diagnosis.** The general study cohort entry date (CED) must be preceded by, or coincide with, a record of a psoriasis diagnosis code or other method of ascertainment of psoriasis e.g., use of topical vitamin D3 derivatives or a recording of a disease specific copayment exemption code.

**Qualification of indication for receiving biological therapy (optional).** If relevant, each site may impose additional criteria that ascertain that psoriasis is the most likely indication for the biological treatment dispensed at the CED. This could for example be a requirement for dermatological specialty associated to the encounter or prescriber.

#### *Exclusion Criteria*

**Probable other indication for receiving biological therapy.** The general study CED must not be preceded by any diagnosis (or other means of ascertainment) of clinical conditions that could lead to treatment with any of the drugs evaluated in the BRAHMS study e.g., Crohn's disease, ulcerative colitis, suppurative hidradenitis, or inflammatory arthritis. Psoriasis arthritis does not lead to exclusion but is to be adjusted for in the statistical analysis.

The analysis specific cohorts are then created from the general study cohort by applying analysis specific in- and exclusion criteria, which vary across analyses. For the active comparator cohort studies, in- and exclusion criteria are implemented relative to the cohort entry date (CED); for the case-time-control studies, they are implemented relative to the event date for cases and the index dates for controls. In- and exclusion criteria for study specific cohorts are described in **Box 2** and visualized in **Figure 2**.

**Box 2.** In- and exclusion criteria for analysis specific cohorts (may vary across analyses) in the active comparator cohort design and the case-time-control design.

*Inclusion criteria*

**Minimum registry coverage.** Only individuals with a minimum medical and drug coverage of 183 days prior to the cohort entry date (CED) (730 days for cancer) are included in the active comparator cohort studies, whereas 365 days are required in the case-time-control studies to ensure coverage before the first reference date.

**Age.** Only individuals who are 18 years or older on the CED are included in the active comparator cohort studies, whereas a minimum age of 21 is required in the case-time-control studies to ensure that individuals are at least 18 years on the first reference date.

**Non-bionäive.** Only individuals with at least one prior treatment of another biologic than the drug of interest are included in the active comparator studies. A prior treatment must be recorded at least once within 365 days before the CED. Of note, to avoid potential carry-over effect, prior treatment with brodalumab is not allowed when considering CEDs for active comparators.

**At least one period of brodalumab use.** Specific criterion for the case-time-control studies. Only inclusion of individuals in the case-time-control studies who have a period of use of brodalumab within 730 days prior to the event date/index date.

*Exclusion criteria*

**History of outcome.** Individuals with a recording of the outcome (or part of the outcome or history related to the outcome) prior to the CED are excluded.

**Previous use of drug of interest.** Individuals who have been using the drug of interest (evaluated at substance level) prior to the CED are excluded from the active comparator cohort design, e.g., prior users of brodalumab are excluded from the brodalumab treatment group.

*Study drugs*

1  
2  
3 Brodalumab is indicated for the treatment of moderate to severe plaque psoriasis in adult  
4 patients who are candidates for systemic therapy. The recommended dose is 210 mg  
5 administered by subcutaneous injection at weeks 0, 1, and 2 followed by 210 mg every 2 weeks.  
6  
7 Brodalumab is usually administered in a hospital setting or in specialist practice, but patients may  
8 self-inject after careful instruction[20].  
9  
10

11  
12  
13 Comparator drugs used in the active-comparator cohort design include the following:  
14

- 15 1. Inhibitors of IL-12 and IL-23 (ustekinumab, including biosimilars whenever available)
- 16 2. Inhibitors of TNF- $\alpha$  (etanercept and adalimumab, including biosimilars whenever available).
- 17 3. Other inhibitors of cytokine IL-17A (secukinumab and ixekizumab, including biosimilars  
18 whenever available)  
19  
20  
21  
22

23 Similar to brodalumab, comparator drugs are all administered by subcutaneous injection. For  
24 this reason, infliximab is not included among the TNF- $\alpha$  inhibitor study drugs as it is solely  
25 given intravenously. This could introduce selection bias by restricting to hospital-treated  
26 patients. The dosing interval varies from once a week for TNF- $\alpha$  inhibitors to every 12 weeks  
27 for ustekinumab.  
28  
29  
30

### 31 32 33 34 35 ***Exposure definition*** 36

37 Episodes covered by treatment with study drugs are created for every individual in the general  
38 study cohort within the individual's eligibility period by assigning a dispensing duration  
39 corresponding to the expected time covered by that dispensing. Dispensing durations of the  
40 same biologic are then combined into continuous treatment episodes if there are no gaps  
41 between them. Finally, overlapping time in treatment episodes of different biologics are resolved  
42 by formally terminating any treatment episode when a treatment episode with another biologic  
43 begins (**Figure 3**). The result is a non-overlapping sequence of treatment episodes for each  
44 individual. At no point in time are persons considered exposed to more than one study drug.  
45 This is in line with the dominating treatment regimen in psoriasis, where biologics are prescribed  
46 as monotherapy or in combination with topical treatments[21,22].  
47  
48  
49  
50  
51  
52  
53  
54

55 Dispensing durations are estimated separately for each biologic at each site using the waiting time  
56 distribution (WTD) method, which is a data-driven approach[23]. The WTD method estimates  
57 the interarrival density function, i.e., the distribution of gap time between dispensings inside a  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

treatment episode for patients in continuous treatment. For this distribution, we will use the time corresponding to the 95<sup>th</sup> percentile as dispensing duration. This approach mitigates challenges resulting from the heterogeneous availability of data on dispensing durations for biologics, such as recordings of dose or days covered, across sites.

**Outcome**

Study outcomes include:

Serious infections, i.e., the composite of serious acute infections and incident serious chronic infections. A serious acute infection is defined as any community-acquired acute bacterial, viral, or fungal infection that is severe enough to lead to hospitalization or death. An incident serious chronic infection is defined as a new infection with tuberculosis, hepatitis B or C, or other severe viral hepatitis infections, or osteomyelitis either leading to hospitalization or treated at outpatient specialist visits.

Suicidal conduct, i.e., the composite of death by suicide or suicide attempt leading to hospitalization or treatment at outpatient visits.

MACE, i.e., the composite of hospital admissions due to acute myocardial infarction, stroke (including ischemic stroke and haemorrhagic stroke but excluding transient ischemic attack), or cardiovascular death in- or outside hospital.

Cancer, i.e., a diagnosis of malignant neoplasms.

The exact definition of these outcomes may vary across sites, according to availability and structure of data.

**Analysis**

*Case-time-control design specifications*

In the case-time-control design, each individual’s exposure status at the index date is compared to four reference dates in the same individual’s past. The index date is the date of the outcome. Control individuals without outcomes are sampled 4:1 by a risk set sampling strategy, matched

by age and sex and assigned an index date identical to their corresponding case. Only cases and controls who have been exposed to brodalumab either at the index date or at least at one of the reference dates contribute to the analysis. An individual is considered exposed to brodalumab at an index- or reference date if they occurred within a brodalumab treatment episode.

Consistent with standard recommendations regarding case-time-control design, a washout interval is interspersed between the index date and the latest of the reference dates to minimize carry over between index and reference dates[17]. We chose a fairly long interval between each index date and reference point, 4 months, to minimize autocorrelation by exposure[24]. The case-time-control design employed is illustrated in **Figure 4**.

Due to the inherently matched nature of this design, conditional logistic regression is used to calculate ORs [15].

#### *Active comparator cohort design specifications*

The active comparator cohort design addresses the pragmatic, clinical question of whether the outcome association is stronger for brodalumab than for comparable drugs, as rates of events are compared between users of brodalumab and users of other biological treatments.

Adaptations of the active comparator cohort design are used to investigate the effects of both new use, ongoing use without restricting to new users, ever use and cumulative duration of use of brodalumab depending on the expected biological mechanism behind a potential association between use of brodalumab and the outcome.

For serious infections and SIB, the potential effect of brodalumab is likely to emerge shortly after initiation and is expected to persist during ongoing exposure. The associations are therefore investigated using the active comparator, new user cohort design as well as the variation hereof adapted to ongoing use without restriction to new users. In the active comparator, new user cohort analysis only incident treatment episodes of the drug of interest are included. That is, individuals are only considered exposed while being treated with the drug of interest for the first time. Subsequent treatment episodes with the same drug do not contribute to the analysis. The analysis adapted to ongoing use without restricting to new users only differs by also allowing subsequent treatment episodes.

For cancer as the outcome, an effect of brodalumab may manifest with some latency, possibly even after termination of treatment. Therefore, the active comparator study adapted to ever use



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

is applied. In this analysis, an individual’s exposure status remains unchanged even if the drug of interest is discontinued or another biologic is initiated. To avoid unduly complicated histories of exposure patterns in this analysis and undue assumptions, the comparison is with all active comparators without making distinctions at substance level or substance group level.

When investigating a potential association with cancer, it is also reasonable to assume a cumulative dose response association, i.e., users with high cumulative doses have higher risk than users with low cumulative doses, all things being equal. A methodological challenge is in the comparative element; to assess whether the cumulative dose-response effect is more pronounced for brodalumab than for its active comparators. For this purpose, we developed an active comparator cohort design, adapted to cumulative exposure effects. We establish running cumulative accounts of exposed person-time from brodalumab treatment episodes as well as running accounts of exposed person-time from treatment episodes of any study biologics, including brodalumab. Only incident treatment episodes with a starting date within an individual’s eligibility period contributes to the analysis (**Figure 5**).

For MACE as the outcome, the underlying biological mechanisms behind a potential association are unknown i.e., neither an immediate effect of ongoing exposure nor a delayed effect of long-term use can be ruled out. Thus, all four variations of the active comparator cohort design are used to investigate a potential association between brodalumab and the risk of MACE.

For the analysis adapted to cumulative exposure effects, a Cox-regression is performed with cumulative exposure to any biologic and to brodalumab included in parallel as time-dependent variables. The potential incremental effect associated with brodalumab cumulative exposure, above and beyond the cumulative exposure to study biologics in general, is estimated by the coefficient for the cumulative dose of brodalumab in that regression. The model allows for concurrent adjustment for other relevant covariates if they are available.

A standard meta-analysis, including country-specific estimates from the main analysis of each outcome is performed for both the active comparator cohort design and the case-time-control design.

**Potential limitations**

The active comparator cohort design is vulnerable to confounding due to differences in patient characteristics between the brodalumab and active comparator groups. This is accounted for in several ways. First, to optimize comparability between users of brodalumab and users of active comparators, only treatment episodes that are incident or preceded by an incident treatment episode within an individual's eligibility period are included. A minimum look-back of 183 days is required to ensure incident use. Also, as brodalumab is considered a second-line treatment, we require all users of comparator drugs to have switched from another biologic anti-psoriatic drug before cohort entry. Finally, in the standard active comparator analyses, measured confounding is addressed by using propensity score matching as the main tool[25]. IPTW (Inverse Probability of Treatment Weighting) are applied in a sensitivity analysis.

In both the active comparator cohort design and the case-time-control design, analyses are performed with and without restriction to individuals without a history of the outcome of interest to limit confounding by indication. Time-dependent confounding by disease activity is handled by adjusting for measures of disease activity and proxies hereof whenever this is possible.

Considerable heterogeneity in the structure, quality, availability (e.g., cause of death) and coding practice across sites is expected. Some of these problems might be mitigated by using a common data model (CDM) and a centralized development of analysis. In addition, there will be validation studies of suicidal conduct in selected regions, albeit no general case validation is planned.

The mapping of exposure status involves critical decisions with an inherent risk of misclassification. This may threaten the validity of both designs. Consequently, the estimation of dispensing durations using the waiting time distribution is subject to several sensitivity analyses.

The range of subgroup-, sensitivity-, and supplementary analyses performed to elucidate potential biases are described in **Supplementary Table 1**.

### ***Data management***

The data infrastructure of the BRAHMS study is based on a distributed database network which applies a CDM designed specifically for the study. The BRAHMS CDM provides a detailed specification of an agreed data structure and codebook, that each site must transform their local

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

register data into. A quality assurance program is used to confirm compliance. The result of data transformation is a locally populated instance of the BRAHMS CDM containing all relevant study data structured identically across sites, but accessible only by the local site. The coordinating site creates analytical programs to be run locally at each site. Only aggregate results from these programs are shared across sites. This strategy is described in the ENCePP Guide on Methodological Standards in Pharmacoepidemiology, in the section on multi-database studies[26].

The heterogeneity of e.g., available data sources, coding practices, and validity of codes across sites is a limitation that necessitates a flexible method of adapting study variable definitions (required codes, settings, number of occurrences, assessment windows, etc.) to the requirement of each site. A component-composite framework is implemented[27,28]. In this framework, each study variable is defined locally as a logical composite of one or more components. Each component is a specification of codes e.g., diagnoses codes or ATC codes, and contextual conditions e.g., “only inpatient contacts”, that records in the CDM must fulfil[27,28].

**Other**

*Study sponsorship: monitoring, audit, quality control and quality assurance*

The study sponsor is the University of Southern Denmark, which undertakes quality assurance. The study is funded by Leo Pharma, the market authorization holder of brodalumab, as part of an EMA mandated Post Authorization Safety Study[29].

*Access to data*

Data will be available for local investigators only. Data extraction and analyses are performed locally, and results are transferred at an aggregate level to SDU. Individual-level data will be unavailable across the other sites and to third parties outside the BRAHMS collaboration.

*Study registration*

The BRAHMS study is registered in the EU - PASS register (reference number EUPAS30280).

## **Ethics and dissemination**

The BRAHMS study is performed in accordance with International Society of Pharmacoepidemiology (ISPE) Good Pharmacoepidemiology Practice guidance[30]. The study is approved by relevant authorities in Denmark, Norway, Sweden, the Netherlands, Germany, and Italy in line with the relevant legislation at each site (detailed statements can be found in Appendix A). The General Data Protective Regulation (GDPR) will be followed, and data confidentiality will be ensured by the distributed network approach to data exchange. The results of the study will be published in peer-reviewed scientific journals and presented at relevant conferences.

## **Patient and public involvement**

Patients and/or the public were not involved in this study.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Discussion**

The BRAHMS study design and innovative data infrastructure serves as an example of how a large multi-database safety study can be conducted by efficiently using data sources and IT, including follow up of patients by record linkage. Through the distributed network methodology, the CDM, and the centralized programming, the risk for breach of data confidentiality is minimal and a high analytical standard is achieved.

The results from the BRAHMS study will be of substantial interest to patients with moderate to severe psoriasis and their treating physicians, irrespective of its findings. If the BRAHMS study reveals associations with any of the outcomes, further regulatory actions would be initiated to limit their impact. If BRAHMS identifies no associations with any of the outcomes, brodalumab can be used confidently at its proper position in the armamentarium of biological anti-psoriatic agents. Treatment failure occurs frequently with biological psoriasis treatment[31], and it is vital to have multiple medications that offers new treatment alternatives when others have failed.

As an important collateral benefit of the study, we build network, experience, methodology and infrastructure which allows for a timely and scientifically rigorous investigation of future safety issues, especially in the area of biologic drug use in psoriasis and other immune mediated inflammatory diseases.

### Author's contribution

Conception and design: MR, PBJ, LSR, JH, AE, KF, KG, DH, UH, ØK, JR, WS, SS, ES, EH, RH, GT, UK, ACR, VB, RG, HS. Writing the article: MR, PBJ, LSR and JH prepared the first draft of the paper. Critical revision of the article: MR, PBJ, LSR, JH, AE, KF, KG, DH, UH, ØK, JR, WS, SS, ES, EH, RH, GT, UK, ACR, VB, RG, HS. Final approval: MR, PBJ, LSR, JH, AE, KF, KG, DH, UH, ØK, JR, WS, SS, ES, EH, RH, GT, UK, ACR, VB, RG, HS. Overall responsibility: MR, PBJ, LSR, JH.

### Funding statement

The current study is funded by LEO Pharma A/S, with funds paid to participating institutions (no personal fees). Award/grant number N/A.

### Competing interest statement

Mette Reilev and Peter Bjødstrup Jensen report participation in research funded by LEO Pharma A/S (no personal fees).

Jesper Hallas reports participation in studies funded by Alcon, Almirall, Astellas, AstraZeneca, Boehringer-Ingelheim, Novo Nordisk, Servier, Pfizer, Menarini Pharmaceuticals, and LEO Pharma, all regulator mandated phase IV studies, all with funds paid to the institution (no personal fees). J Hallas has received teaching fees from Atrium.

Henrik Støvring reports participation in research funded by LEO Pharma A/S (no personal fees). He has received personal consulting fees from Bristol-Myers-Squibb, Novartis, Roche, Merck and Pfizer outside the submitted work. He has received teaching fees from Atrium.

Kari Furu and Øystein Karlstad reports participation in research projects funded by Novo Nordisk and LEO Pharma, all regulator mandated phase IV studies, all with funds paid to the institution (no personal fees).

Elisabeth Smits, Emily Holthuis and Ron Herings are employees of the PHARMO Institute for Drug Outcomes Research. This independent research institute performs financially supported studies for government and related healthcare authorities and several pharmaceutical companies.

Alexander Egeberg has received research funding from Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as consultant and/or speaker from AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, Horizon Therapeutics, and Janssen Pharmaceuticals.

Ursula Kirchmayer, Alessandro Cesare Rosa, and Valeria Belleudi are employees of the Department of Epidemiology ASL Roma1, Lazio Regional Health Service in Rome, Italy. Our publicly funded department performs epidemiological research and receives grants from public national and international organisations. In case of financial support from private organisations, an ethical code of conduct is signed to guarantee transparency and independence.

Karin Gembert, David Hägg and Johan Reutfors are employees of the Centre for Pharmacoepidemiology of the Karolinska Institutet in Sweden, which receives grants from regulatory authorities, pharmaceutical companies, and contract research organizations for performance of drug safety and drug utilization studies.

Ulrike Haug, Wiebke Schäfer and Sarina Schwarz are working at an independent, non-profit research institute, the Leibniz Institute for Prevention Research and Epidemiology – BIPS. Unrelated to this study, BIPS occasionally conducts studies financed by the pharmaceutical industry. Almost exclusively, these are post-authorization safety studies (PASS) requested by health authorities.

Gianluca Trifirò declares participation to advisory boards on topics not related to this paper and sponsored by the following pharmaceutical companies in the last two years: Eli Lilly; Sanofi; Amgen; Novo Nordisk; Sobi; Gilead; Celgene; Daikii Sankyo.

RG is employed by ARS, a public research center participating in pharmacoepidemiology studies funded by public or private institutions and compliant with the ENCePP Code of Conduct. The budget of ARS is partially sustained by such studies.



## References

- 1 Armstrong AW, Mehta MD, Schupp CW, *et al.* Psoriasis Prevalence in Adults in the United States. *JAMA Dermatol* 2021;**157**:940–6. doi:10.1001/jamadermatol.2021.2007
- 2 Parisi R, Iskandar IYK, Kontopantelis E, *et al.* National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ* 2020;**369**:m1590. doi:10.1136/bmj.m1590
- 3 Levin EC, Gupta R, Brown G, *et al.* Biologic fatigue in psoriasis. *J Dermatol Treat* 2014;**25**:78–82. doi:10.3109/09546634.2013.826341
- 4 Lebwohl M, Strober B, Menter A, *et al.* Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. *N Engl J Med* 2015;**373**:1318–28. doi:10.1056/NEJMoa1503824
- 5 Papp KA, Leonardi C, Menter A, *et al.* Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. *N Engl J Med* 2012;**366**:1181–9. doi:10.1056/NEJMoa1109017
- 6 Papp K, Menter A, Leonardi C, *et al.* Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). *Br J Dermatol* 2020;**183**:1037–48. doi:10.1111/bjd.19132
- 7 Hansel TT, Kropshofer H, Singer T, *et al.* The safety and side effects of monoclonal antibodies. *Nat Rev Drug Discov* 2010;**9**:325–38. doi:10.1038/nrd3003
- 8 Puel A, Cypowyj S, Maródi L, *et al.* Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. *Curr Opin Allergy Clin Immunol* 2012;**12**:616–22. doi:10.1097/ACI.0b013e328358cc0b
- 9 Liang SE, Cohen JM, Ho RS. Psoriasis and suicidality: A review of the literature. *Dermatol Ther* 2019;**32**:e12771. doi:10.1111/dth.12771
- 10 Pompili M, Bonanni L, Gualtieri F, *et al.* Suicidal risks with psoriasis and atopic dermatitis: Systematic review and meta-analysis. *J Psychosom Res* 2021;**141**:110347. doi:10.1016/j.jpsychores.2020.110347
- 11 Lebwohl MG, Papp KA, Marangell LB, *et al.* Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials. *J Am Acad Dermatol* Published Online First: October 2017. doi:10.1016/j.jaad.2017.08.024
- 12 Raaby L, Ahlehoff O, de Thurah A. Psoriasis and cardiovascular events: updating the evidence. *Arch Dermatol Res* 2017;**309**:225–8. doi:10.1007/s00403-016-1712-1
- 13 Torres T, Raposo I, Selores M. IL-17 Blockade in Psoriasis: Friend or Foe in Cardiovascular Risk? *Am J Clin Dermatol* 2016;**17**:107–12. doi:10.1007/s40257-015-0166-0
- 14 Peleva E, Exton LS, Kelley K, *et al.* Risk of Cancer in Patients with Psoriasis on Biologic Therapies: A Systematic Review. *Br J Dermatol* Published Online First: 19 July 2017. doi:10.1111/bjd.15830
- 15 Suissa S. The case-time-control design. *Epidemiol Camb Mass* 1995;**6**:248–53. doi:10.1097/00001648-199505000-00010



16 Lund JL, Richardson DB, Stürmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. *Curr Epidemiol Rep* 2015;**2**:221–8. doi:10.1007/s40471-015-0053-5

17 Cadarette SM, Maclure M, Delaney JAC, *et al.* Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology. *Pharmacoepidemiol Drug Saf* 2021;**30**:671–84. doi:10.1002/pds.5227

18 Hallas J, Pottegård A, Wang S, *et al.* Persistent User Bias in Case-Crossover Studies in Pharmacoepidemiology. *Am J Epidemiol* 2016;**184**:761–9. doi:10.1093/aje/kww079

19 Bykov K, Wang SV, Hallas J, *et al.* Bias in case-crossover studies of medications due to persistent use: A simulation study. *Pharmacoepidemiol Drug Saf* 2020;**29**:1079–85. doi:10.1002/pds.5031

20 kyntheum - Summary of product characteristics.  
[https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information\\_en.pdf](https://www.ema.europa.eu/en/documents/product-information/kyntheum-epar-product-information_en.pdf) (accessed 29 Mar 2022).

21 Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykiewicz NM, *et al.* Drug Persistence of Biologic Treatments in Psoriasis: A Swedish National Population Study. *Dermatol Ther* 2021;**11**:2107–21. doi:10.1007/s13555-021-00616-7

22 Menter A, Strober BE, Kaplan DH, *et al.* Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol* 2019;**80**:1029–72. doi:10.1016/j.jaad.2018.11.057

23 Støvring H, Pottegård A, Hallas J. Determining prescription durations based on the parametric waiting time distribution. *Pharmacoepidemiol Drug Saf* 2016;**25**:1451–9. doi:10.1002/pds.4114

24 Jensen AKG, Gerds TA, Weeke P, *et al.* On the validity of the case-time-control design for autocorrelated exposure histories. *Epidemiol Camb Mass* 2014;**25**:110–3. doi:10.1097/EDE.0000000000000001

25 Stürmer T, Wyss R, Glynn RJ, *et al.* Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs. *J Intern Med* 2014;**275**:570–80. doi:10.1111/joim.12197

26 1.ENCePPMethodsGuideRev.9.pdf.  
[https://www.encepp.eu/standards\\_and\\_guidances/documents/1.ENCePPMethodsGuideRev.9.pdf](https://www.encepp.eu/standards_and_guidances/documents/1.ENCePPMethodsGuideRev.9.pdf) (accessed 8 Mar 2022).

27 Roberto G, Leal I, Sattar N, *et al.* Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project. *PloS One* 2016;**11**:e0160648. doi:10.1371/journal.pone.0160648

28 Gini R, Dodd CN, Bollaerts K, *et al.* Quantifying outcome misclassification in multi-database studies: The case study of pertussis in the ADVANCE project. *Vaccine* 2020;**38** Suppl 2:B56–64. doi:10.1016/j.vaccine.2019.07.045

29 BRAHMS study ENCePP registration.  
<https://www.encepp.eu/encepp/viewResource.htm?id=43504> (accessed 21 Apr 2022).

- 30 Public Policy Committee, International Society of Pharmacoepidemiology. Guidelines for  
 31 good pharmacoepidemiology practice (GPP): Guidelines for good pharmacoepidemiology  
 32 practice. *Pharmacoepidemiol Drug Saf* 2016;**25**:2–10. doi:10.1002/pds.3891
- 33 Ai M, R G. Biologic Drug Survival in Psoriasis: A Systematic Review & Comparative  
 34 Meta-Analysis. *Front Med* 2021;**7**. doi:10.3389/fmed.2020.625755

## Acknowledgements

None

## Figure Legends

**Figure 1.** Design diagram for the building of the general study cohort. Light blue: inclusion criteria; Red: exclusion criteria; Grey: Eligibility period. The cohort entry date must lie within the study period, and it must be the earliest possible date that fulfils all inclusion and exclusion criteria.

**Figure 2.** Design diagrams for inclusion- and exclusion criteria implemented in A) the active comparator cohort studies and B) the case-time-control studies. Light blue: inclusion criteria; Red: exclusion criteria; Grey: follow-up window.

**Figure 3.** Illustration of the process of creating treatment episodes for a person in the general study cohort. Each colour in the top 4 panels represent a specific biologic substance used in the treatment of psoriasis. Infliximab (yellow) is not a study drug but dispensing of Infliximab are included in the following steps anyway. Circles represent dispensing timepoints and lines represent dispensing duration. (1) All dispensing of biologics used to treat psoriasis within the eligibility window are identified. A dispensing duration is added to each dispensing. (2) Within each drug, overlapping durations are combined. (3) Between drugs, non-overlapping episodes are created by always truncating a previous episode when it is interrupted by a dispensing by another drug. (4) Episodes for non-study biologics are removed. The result is 6 treatment episodes for 3 different study drugs. (5) Episodes are also created on substance group level, by collapsing substance level episodes by their substance group. This results in 4 treatment episodes for 2 different substance groups.


**Figure 4.** In the case-time-control design, exposure status is compared on event-/index date and reference dates. The first four individuals are discordant (i.e., they have periods of both non-use and use of brodalumab) while individual number five is concordant (i.e., has the same exposure status in all windows, either consistently use or consistently non-use of brodalumab), and therefore does not contribute to the analysis. The black dots represent the date of the outcome event (for cases) or the index date (for controls), while the black arrows mark the reference dates. The shaded areas indicate the time exposed to brodalumab.

**Figure 5.** Methods of the cumulative comparative cohort design. The graph illustrates the accumulation of doses during the study period of an individual who is given three different drugs: TNF- $\alpha$  inhibitors, brodalumab, and IL-12 and IL-23 inhibitors. For each time point, a running account of the cumulative dosing of each drug is worked up. For example, when the IL-

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


12 and IL-23 inhibitor is initiated, the individual has a cumulative dose of TNF- $\alpha$  inhibitors, stemming from the first interval, and a cumulative dose of brodalumab stemming from the second interval. As the third interval passes, the individual gradually increases the cumulative dose of IL-12 and IL-23 inhibitor while the cumulative doses for brodalumab and TNF- $\alpha$  inhibitors remain constant. At no point in time during exposure the cumulative amount of these three drugs is identical to another point in time. In the analytic dataset, all non-brodalumab biologics are to be grouped together, and a running account of cumulative brodalumab and cumulative non-brodalumab biologics are to be calculated. The metric used for the cumulative analysis is cumulative time treated, rather than a cumulative dose in mg or defined daily doses. The shaded boxes illustrate the lag-time with respect to any biologic exposure (i.e., the time interval where any occurrence of a cancer cannot be expected to be caused by time spent in a given cumulative exposure).

For peer review only




**Figure 1.** Design diagram for the building of the general study cohort. Light blue: inclusion criteria; Red: exclusion criteria; Grey: Eligibility period. The cohort entry date must lie within the study period, and it must be the earliest possible date that fulfils all inclusion and exclusion criteria.


A)




B)




**Figure 2.** Design diagrams for inclusion- and exclusion criteria implemented in A) the active comparator cohort studies and B) the case-time-control studies. Light blue: inclusion criteria; Red: exclusion criteria; Grey: follow-up window.



**Figure 3.** Illustration of the process of creating treatment episodes for a person in the general study cohort. Each color in the top 4 panels represent a specific biologic substance used in the treatment of psoriasis. Infliximab (yellow) is not a study drug but dispensing of Infliximab are included in the following steps anyway. Circles represent dispensing timepoints and lines represent dispensing duration. (1) All dispensing of biologics used to treat psoriasis within the eligibility window are identified. A dispensing duration is added to each dispensing. (2) Within each drug, overlapping durations are combined. (3) Between drugs, non-overlapping episodes are created by always truncating a previous episode when it is interrupted by a dispensing by another drug. (4) Episodes for non-study biologics are removed. The result is 6 treatment episodes for 3 different study drugs. (5) Episodes are also created on substance group level, by collapsing substance level episodes by their substance group. This results in 4 treatment episodes for 2 different substance groups.



**Figure 4.** In the case-time-control design, exposure status is compared on event-/index date and reference dates. The first four individuals are discordant (i.e., they have periods of both non-use and use of brodalumab) while individual number five is concordant (i.e., has the same exposure status in all windows, either consistently use or consistently non-use of brodalumab), and therefore does not contribute to the analysis. The black dots represent the date of the outcome event (for cases) or the index date (for controls), while the black arrows mark the reference dates. The shaded areas indicate the time exposed to brodalumab.



**Figure 5.** Methods of the cumulative comparative cohort design. The graph illustrates the accumulation of doses during the study period of an individual who is given three different drugs: TNF- $\alpha$  inhibitors, brodalumab, and IL-12 and IL-23 inhibitors. For each time point, a running account of the cumulative dosing of each drug is worked up. For example, when the IL-12 and IL-23 inhibitor is initiated, the individual has a cumulative dose of TNF- $\alpha$  inhibitors, stemming from the first interval, and a cumulative dose of brodalumab stemming from the second interval. As the third interval passes, the individual gradually increases the cumulative dose of IL-12 and IL-23 inhibitor while the cumulative doses for brodalumab and TNF- $\alpha$  inhibitors remain constant. At no point in time during exposure the cumulative amount of these three drugs is identical to another point in time. In the analytic dataset, all non-brodalumab biologics are to be grouped together, and a running account of cumulative brodalumab and cumulative non-brodalumab biologics are to be calculated. The metric used for the cumulative analysis is cumulative time treated, rather than a cumulative dose in mg or defined daily doses. The shaded boxes illustrate the lag-time with respect to any biologic exposure (i.e., the time interval where any occurrence of a cancer cannot be expected to be caused by time spent in a given cumulative exposure).



1  
2  
3  
4 **Supplementary Material**  
5

6  
7  
8 **Appendix A**  
9

10 **Statement regarding approvals by relevant authorities**  
11  
12

13 Denmark:  
14 According to Danish law, studies based entirely on registry data do not require approval from an ethics review  
15 board. The study was registered at the repository of the University of Southern Denmark (11.423) and data were  
16 available from the Danish Health Data Authority (FSEID00005818). Due to legal reasons, individual-level data  
17 cannot be shared by the authors.  
18

19  
20 Norway:  
21  
22 The study was approved by the Regional Ethical Committee B, South East Norway (ref 547020/REK sør-øst B).  
23 Due to legal reasons, individual-level data cannot be shared by the authors.  
24

25  
26 Sweden:  
27  
28 The study was approved by the Swedish Ethical Review Authority (no. 2020/07088–02/9). Due to legal reasons,  
29 individual-level data cannot be shared by the authors.  
30

31  
32 The Netherlands:  
33  
34 This study analysed de-identified data from the PHARMO Database Network; therefore, the study was exempt  
35 from ethical review and informed consent was not required. The data in this study are available from the  
36 PHARMO Database Network. As restrictions apply to the availability of these data, they are not publicly  
37 available.  
38

39  
40 Germany:  
41  
42 In Germany, the utilisation of health insurance data for scientific research is regulated by the Code of Social Law.  
43 All involved health insurance providers as well as the German Federal Office for Social Security and the Senator  
44 for Health, Women and Consumer Protection in Bremen as their responsible authorities approved the use of  
45 GePaRD data for this study. Informed consent for studies based on claims data is required by law unless  
46 obtaining consent appears unacceptable and would bias results, which was the case in this study. According to  
47 the Ethics Committee of the University of Bremen studies based on GePaRD are exempt from institutional  
48 review board review.  
49

50  
51 Italy:  
52  
53 In Italy retrospective studies based on administrative health care data require only notification to Ethical  
54 Committees. Department of Epidemiology of Lazio notified the protocol to EC on behalf of all centres. In  
55 addition, special agreements for the access and analyses of claims data are in place between each centre and  
56 respective data provider. For the region of Tuscany, the study has been included in the institutional program of  
57 ARS Toscana. Due to legal reasons, individual-level data cannot be shared by the authors.  
58  
59  
60

**Supplementary Table 1.** An overview of main-, supplementary- and sensitivity analyses of the association between use of brodalumab and suicide attempts, serious infections, MACE and cancer. Each bullet under *supplementary and sensitivity analyses* describes how the analysis differs from the main analysis.

|  | Case-time-control design  | Active-comparator cohort design   |
|--|---|---|
| <i>Suicide attempts</i>  |   |   |
| <b>Main analyses</b>   | <p>Event/index date: First occurrence of the composite of fatal and non-fatal suicide attempts during eligibility period for cases and corresponding date for controls</p> <p>Study population: Restricted to brodalumab users without a history of psychiatric disease, suicide attempt, use of anti-depressants or use of lithium</p> <p>Exposure: Brodalumab</p> <p>Time intervals: 4 months</p> <p>Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution</p> <p>Adjustment for time varying activity</p> <p>No comparison to contrasting use</p> | <p>Cohort entry: Start of incident treatment episode of drug of interest</p> <p>Study population: Restricted to individuals without a history of psychiatric disease, suicide attempt, use of anti-depressants or use of lithium</p> <p>Outcome: First occurrence of the composite of fatal and non-fatal suicide attempts during eligibility period</p> <p>Exposure: Brodalumab vs. TNF-alpha inhibitors, IL-12 and IL-23, other inhibitors of IL-17(substance group level)</p> <p>Confounder adjustment: 1:4 propensity score matching with replacement</p> <p>Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution</p> |
| <b>Supplementary and sensitivity analyses</b><br>(Differs from main analysis by) | <ol style="list-style-type: none"> <li>1. Subgroup analysis with comparison to contrasting use</li> <li>2. Study population: No restriction by psychiatric history</li> <li>3. Time intervals: 2 months</li> <li>4. Time intervals: 6 months</li> <li>5. No adjustment for time varying activity</li> <li>6. Outcome: Death by suicide</li> <li>7. Outcome: First suicide attempt during eligibility period</li> </ol>  | <ol style="list-style-type: none"> <li>1. Study population: No restriction by psychiatric history</li> <li>2. Cohort entry: Not restricted to incident treatment episode</li> <li>3. Confounder adjustment: IPTW</li> <li>4. Exposure: Brodalumab vs. ustekinumab, etanercept, adalimumab, secukinumab, and ixekizumab (substance level)</li> <li>5. Outcome: Death by suicide</li> <li>6. Outcome: First suicide attempt during eligibility period</li> </ol>  |

|    |  |  |
|----|--|--|
| 1  |  |  |
| 2  | 8. Method of dispensing duration estimation: WTD, 90 <sup>th</sup> percentile,   | 7. Method of dispensing duration estimation: WTD, 90 <sup>th</sup> percentile,   |
| 3  | log-normal backward recurrence distribution                                      | log-normal backward recurrence distribution                                      |
| 4  |  |  |
| 5  | 9. Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile,   | 8. Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile,   |
| 6  | Weibull distribution   | Weibull distribution   |
| 7  |  |  |
| 8  |  |  |
| 9  |  |  |
| 10 | <hr/>  |  |
| 11 | <i>Serious infections</i>  |  |
| 12 | <b>Main analyses</b>   |  |
| 13 | Event/index date: First occurrence of a serious infection i.e., the              | Cohort entry: Start of incident treatment episode of drug of interest            |
| 14 | composite of acute serious infections and chronic infections, during             | Study population: Restricted to individuals without a history of                 |
| 15 | the eligibility period   | chronic infections   |
| 16 |  | Outcome: first occurrence of a serious infection i.e., the composite of          |
| 17 | Study population: Restricted to brodalumab users without a history of            | acute serious infections and chronic infections, during the eligibility          |
| 18 | chronic infections   | period   |
| 19 | Exposure: brodalumab   | Exposure: Brodalumab vs. TNF-alpha inhibitors, IL-12 and IL-23,                  |
| 20 | Time intervals: 4 months   | other inhibitors of IL-17(substance group level)                                 |
| 21 |  |  |
| 22 | Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, log- | Confounder adjustment: 1:4 propensity score matching with                        |
| 23 | normal backward recurrence distribution  | replacement  |
| 24 | Adjustment for time varying activity   | Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, log- |
| 25 |  | normal backward recurrence distribution  |
| 26 | No comparison to contrasting use   |  |
| 27 |  |  |
| 28 |  |  |
| 29 |  |  |
| 30 | <b>Supplementary and</b>   |  |
| 31 | <b>sensitivity analyses</b>  |  |
| 32 | (Differs from main   | 1. Study population: Restricted to individuals without a history of              |
| 33 | analysis by)   | either acute serious infection or chronic infections                             |
| 34 |  | 2. Cohort entry: Not restricted to incident treatment episode                    |
| 35 |  | 3. Confounder adjustment: IPTW   |
| 36 |  | 4. Exposure: Brodalumab vs. ustekinumab, etanercept, adalimumab,                 |
| 37 |  | secukinumab, and ixekizumab (substance level)                                    |
| 38 |  | 5. Outcome: First acute serious infection during the eligibility period          |
| 39 |  |  |
| 40 |  |  |
| 41 |  |  |
| 42 |  |  |
| 43 |  |  |
| 44 |  |  |
| 45 |  |  |
| 46 |  |  |

7. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

8. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

6. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

7. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

## MACE

### Main analyses

Event/index date: First occurrence of MACE during eligibility period

Study population: All brodalumab users. No restriction by outcome

Exposure: Brodalumab

Time intervals: 4 months

Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution

Adjustment for time varying activity

No comparison to contrasting use

Cohort entry: Start of incident treatment episode of drug of interest

Study population: No restriction by history MACE

Outcome: first occurrence of a MACE during the eligibility period

Exposure: Brodalumab vs. TNF-alpha inhibitors, IL-12 and IL-23, other inhibitors of IL-17(substance group level)

Confounder adjustment: 1:4 propensity score matching with replacement

Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, log-normal backward recurrence distribution

### Supplementary and sensitivity analyses

(Differs from main analysis by)

1. Subgroup analysis with comparison to contrasting use

2. Study population: Restricted to brodalumab users without a history of MACE, acute coronary syndrome, or transitory ischemic attack

3. Time intervals: 2 months

4. Time intervals: 6 months

5. No adjustment for time varying activity

6. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

7. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

1. Study population: Restricted to individuals without a history of MACE, acute coronary syndrome, or transitory ischemic attack

2. Cohort entry: Not restricted to incident treatment episode

3. Confounder adjustment: IPTW

4. Exposure: Brodalumab vs. ustekinumab, etanercept, adalimumab, secukinumab, and ixekizumab (substance level)

5. Exposure: Ever use of brodalumab vs. any active comparator

6. Cumulative use of brodalumab vs. any biologics used in the treatment of psoriasis

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

7. Method of dispensing duration estimation: WTD, 90<sup>th</sup> percentile, log-normal backward recurrence distribution

8. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile, Weibull distribution

Cancer

|  |                |   |
|--|----------------|---|
| Main analyses                          | Not applicable | Cohort entry: Start of any treatment episode but restricted to episodes that are incident or follow an incident episode within eligibility period |
|  |                | Study population: Restricted to individuals without a history of cancer   |
|  |                | Outcome: First cancer diagnosis ever  |
|  |                | Exposure: Ever use of brodalumab vs. any active comparator  |
|  |                | Lag-time: 12 months   |
|  |                | Confounder adjustment: 1:4 propensity score matching with replacement   |
|  |                | Method of dispensing duration estimation: WTD, 95 <sup>th</sup> percentile, log-normal backward recurrence distribution                           |
| Supplementary and sensitivity analyses |                | 1. Study population: No restriction by cancer history   |
| (Differs from main analysis by)        |                | 2. Lag-time: 6 months   |
|  |                | 3. Lag-time: 24 months  |
|  |                | 4. Outcome: first cancer diagnosis ever excl. NMSC  |
|  |                | 5. Confounder adjustment: IPTW  |
|  |                | 6. Cumulative use of brodalumab vs. any biologics used in the treatment of psoriasis  |
|  |                | 7. Method of dispensing duration estimation: WTD, 90 <sup>th</sup> percentile, log-normal backward recurrence distribution                        |

8. Method of dispensing duration estimation: WTD, 95<sup>th</sup> percentile,  
Weibull distribution

---

WTD: Waiting time distribution; IPTW: Inverse probability of treatment weighting; TNF: Tumor necrosis factor; MACE: Major adverse cardiac events;  
NMSC: Non-melanoma skin cancer

For peer review only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46

For peer review only